Publications
Selected publications
- Partial pancreatoduodenectomy versus duodenum-preserving pancreatic head resection in chronic pancreatitis: the multicentre, randomised, controlled, double-blind ChroPac trial (Journal article - 2017)
- Guidelines for the understanding and management of pain in chronic pancreatitis (Journal article - 2017)
- Pancreatic Anastomosis After Pancreatoduodenectomy: A Position Statement By The International Study Group Of Pancreatic Surgery (ISGPS) (Journal article - 2017)
- Outcomes From Minimal Access Retroperitoneal and Open Pancreatic Necrosectomy in 394 Patients With Necrotizing Pancreatitis (Journal article - 2016)
- What Is the Best Way to Identify Malignant Transformation Within Pancreatic IPMN: A Systematic Review and Meta-Analyses (Journal article - 2015)
- A Multicenter, Randomized, Double-Blinded, Clinical Trial Comparing Cattell-Warren and Blumgart Anastomoses Following Partial Pancreatoduodenectomy: PANasta Trial. (Journal article - 2022)
- International consensus guidelines on the role of diagnostic endoscopic ultrasound in the management of chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club. (Journal article - 2020)
- Emerging Phenotype of Severe Acute Respiratory Syndrome-Coronavirus 2-associated Pancreatitis. (Journal article - 2020)
- Single port retroperitoneal pancreatic necrosectomy for the treatment of extra-pancreatic walled off necrotic collections. (Journal article - 2021)
- The in situ near-total pancreatectomy (LIVOCADO procedure) for end-staged chronic pancreatitis (Journal article - 2021)
2024
Glycaemic control following total pancreatectomy: room for improvement?
Shapey, I. M., Alfred, J., Sharp, R., Whelan, P., Szatmary, P., Mann, K., . . . Baron, R. D. (2024). Glycaemic control following total pancreatectomy: room for improvement?. HPB : the official journal of the International Hepato Pancreato Biliary Association, 26(8), 1075-1078. doi:10.1016/j.hpb.2024.04.015
Complexity and Experience Grading to Guide Patient Selection for Minimally-invasive Pancreatoduodenectomy: An ISGPS Consensus.
Barreto, S. G., Strobel, O., Salvia, R., Marchegiani, G., Wolfgang, C. L., Werner, J., . . . International Study Group for Pancreatic Surgery. (2024). Complexity and Experience Grading to Guide Patient Selection for Minimally-invasive Pancreatoduodenectomy: An ISGPS Consensus.. Annals of surgery. doi:10.1097/sla.0000000000006454
A prognostic model for use before elective surgery to estimate the risk of postoperative pulmonary complications (GSU-Pulmonary Score): a development and validation study in three international cohorts.
NIHR Global Health Research Unit on Global Surgery., & STARSurg Collaborative. (2024). A prognostic model for use before elective surgery to estimate the risk of postoperative pulmonary complications (GSU-Pulmonary Score): a development and validation study in three international cohorts.. The Lancet. Digital health, 6(7), e507-e519. doi:10.1016/s2589-7500(24)00065-7
Author Correction: Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasis.
Astuti, Y., Raymant, M., Quaranta, V., Clarke, K., Abudula, M., Smith, O., . . . Schmid, M. C. (2024). Author Correction: Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasis.. Nature cancer, 5(5), 808. doi:10.1038/s43018-024-00751-y
Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasis.
Astuti, Y., Raymant, M., Quaranta, V., Clarke, K., Abudula, M., Smith, O., . . . Schmid, M. C. (2024). Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasis.. Nature cancer, 5(5), 774-790. doi:10.1038/s43018-024-00731-2
Type 1 Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment.
Overbeek, K. A., Poulsen, J. L., Lanzillotta, M., Vinge-Holmquist, O., Macinga, P., Demirci, A. F., . . . PrescrAIP Study Group. (2024). Type 1 Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment.. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 22(5), 994-1004.e10. doi:10.1016/j.cgh.2023.12.010
Macrophage-fibroblast JAK/STAT dependent crosstalk promotes liver metastatic outgrowth in pancreatic cancer.
Raymant, M., Astuti, Y., Alvaro-Espinosa, L., Green, D., Quaranta, V., Bellomo, G., . . . Schmid, M. C. (2024). Macrophage-fibroblast JAK/STAT dependent crosstalk promotes liver metastatic outgrowth in pancreatic cancer.. Nature communications, 15(1), 3593. doi:10.1038/s41467-024-47949-3
Data from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
Luckett, T., Abudula, M., Ireland, L., Glenn, M., Bellomo, G., Stafferton, R., . . . Mielgo, A. (2024). Data from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis. doi:10.1158/0008-5472.c.7075692
Data from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
Luckett, T., Abudula, M., Ireland, L., Glenn, M., Bellomo, G., Stafferton, R., . . . Mielgo, A. (2024). Data from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis. doi:10.1158/0008-5472.c.7075692.v1
Mesothelin secretion by pancreatic cancer cells co-opts macrophages and promotes metastasis
Mielgo Iza, A. (n.d.). Mesothelin secretion by pancreatic cancer cells co-opts macrophages and promotes metastasis. Cancer Research. doi:10.1158/0008-5472.CAN-23-1542
Supplementary Data from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
Luckett, T., Abudula, M., Ireland, L., Glenn, M., Bellomo, G., Stafferton, R., . . . Mielgo, A. (2024). Supplementary Data from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis. doi:10.1158/0008-5472.25224576.v1
Supplementary Data from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
Luckett, T., Abudula, M., Ireland, L., Glenn, M., Bellomo, G., Stafferton, R., . . . Mielgo, A. (2024). Supplementary Data from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis. doi:10.1158/0008-5472.25224576
Supplementary Figure legends from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
Luckett, T., Abudula, M., Ireland, L., Glenn, M., Bellomo, G., Stafferton, R., . . . Mielgo, A. (2024). Supplementary Figure legends from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis. doi:10.1158/0008-5472.25224573
Supplementary Figure legends from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
Luckett, T., Abudula, M., Ireland, L., Glenn, M., Bellomo, G., Stafferton, R., . . . Mielgo, A. (2024). Supplementary Figure legends from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis. doi:10.1158/0008-5472.25224573.v1
Supplementary Figures from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
Luckett, T., Abudula, M., Ireland, L., Glenn, M., Bellomo, G., Stafferton, R., . . . Mielgo, A. (2024). Supplementary Figures from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis. doi:10.1158/0008-5472.25224567
Supplementary Figures from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
Luckett, T., Abudula, M., Ireland, L., Glenn, M., Bellomo, G., Stafferton, R., . . . Mielgo, A. (2024). Supplementary Figures from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis. doi:10.1158/0008-5472.25224567.v1
Supplementary Tables from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
Luckett, T., Abudula, M., Ireland, L., Glenn, M., Bellomo, G., Stafferton, R., . . . Mielgo, A. (2024). Supplementary Tables from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis. doi:10.1158/0008-5472.25224564
Supplementary Tables from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
Luckett, T., Abudula, M., Ireland, L., Glenn, M., Bellomo, G., Stafferton, R., . . . Mielgo, A. (2024). Supplementary Tables from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis. doi:10.1158/0008-5472.25224564.v1
Abstract PR02: Deep proteomics identifies novel biomarker candidates and molecular pathways of pancreatic cancer-related diabetes
Oldfield, L., Johnson, E., Gutiérrez, E. C., Stott, M., Greenhalf, W., Halloran, C., & Costello, E. (2024). Abstract PR02: Deep proteomics identifies novel biomarker candidates and molecular pathways of pancreatic cancer-related diabetes. Cancer Research, 84(2_Supplement), PR02. doi:10.1158/1538-7445.panca2023-pr02
Inhibition of insulin-like growth factors increases production of CXCL9/10 by macrophages and fibroblasts and facilitates CD8+ cytotoxic T cell recruitment to pancreatic tumours
Freeman, P., Bellomo, G., Ireland, L., Abudula, M., Luckett, T., Oberst, M., . . . Mielgo, A. (n.d.). Inhibition of insulin-like growth factors increases production of CXCL9/10 by macrophages and fibroblasts and facilitates CD8+ cytotoxic T cell recruitment to pancreatic tumours. Frontiers in Immunology, 15. doi:10.3389/fimmu.2024.1382538
2023
Characteristics of BRCA2 families in a familial pancreatic cancer registry
Hopley, P., Downes, J., Law, J., Boughey, A., Halloran, C., & Greenhalf, W. (2023). Characteristics of BRCA2 families in a familial pancreatic cancer registry. Pancreatology, 23, e30-e31. doi:10.1016/j.pan.2023.06.479
Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey.
Badgery, H. E., Muhlen-Schulte, T., Zalcberg, J. R., D'souza, B., Gerstenmaier, J. F., Pickett, C., . . . Pancreatic Cancer Image Biobank Authorship Group. (2023). Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey.. HPB : the official journal of the International Hepato Pancreato Biliary Association, 25(11), 1393-1401. doi:10.1016/j.hpb.2023.07.883
Genetic and functional analysis of chymotrypsin-like protease (CTRL) in chronic pancreatitis
Eiseler, K., Neppl, L., Schmidt, A. W., Rauscher, B., Ewers, M., Masson, E., . . . Witt, H. (2023). Genetic and functional analysis of chymotrypsin-like protease (CTRL) in chronic pancreatitis.. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 23(8), 957-963. doi:10.1016/j.pan.2023.11.002
Genetic and functional analysis of chymotrypsin-like protease (CTRL) in chronic pancreatitis
Eiseler, K., Neppl, L., Schmidt, A. W., Rauscher, B., Ewers, M., Masson, E., . . . Witt, H. (2023). Genetic and functional analysis of chymotrypsin-like protease (CTRL) in chronic pancreatitis. Pancreatology, 23, e64. doi:10.1016/j.pan.2023.06.565
Protein expression mapping reveals molecular mechanisms in pancreatic cancer-related diabetes
Oldfield, L., Stott, M., Greenhalf, W., Halloran, C., & Costello, E. (2023). Protein expression mapping reveals molecular mechanisms in pancreatic cancer-related diabetes. Pancreatology, 23, e153. doi:10.1016/j.pan.2023.06.793
PANC Study (Pancreatitis: A National Cohort Study): national cohort study examining the first 30 days from presentation of acute pancreatitis in the UK
Kosti, A., Borakati, A., Varma, A., Gupta, A., Mustafa, A., Hakeem, A., . . . Bleything, Z. (2023). PANC Study (Pancreatitis: A National Cohort Study): national cohort study examining the first 30 days from presentation of acute pancreatitis in the UK. BJS Open, 7(3). doi:10.1093/bjsopen/zrad008
2022
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.
Ghaneh, P., Palmer, D., Cicconi, S., Jackson, R., Halloran, C. M., Rawcliffe, C., . . . European Study Group for Pancreatic Cancer. (2022). Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.. The lancet. Gastroenterology & hepatology, S2468-1253(22)00348-X. doi:10.1016/s2468-1253(22)00348-x
Evaluation of the prognostic role of aspirin and metformin in the ESPAC 4 randomised trial of adjuvant gemcitabine versus gemcitabine plus capecitabine in patients with resected pancreatic cancer
Ponweera, A., Robinson, M., Jackson, R., Halloran, C., Palmer, D., Hackert, T., . . . Ghaneh, P. (2022). Evaluation of the prognostic role of aspirin and metformin in the ESPAC 4 randomised trial of adjuvant gemcitabine versus gemcitabine plus capecitabine in patients with resected pancreatic cancer. In BRITISH JOURNAL OF SURGERY Vol. 109. doi:10.1093/bjs/znac404.107
Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment
Overbeek, K. A., Poulsen, J., Lanzillotta, M., Vinge-Holmquist, O., Macinga, P., Demirci, A., . . . Rosendahl, J. (2022). Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment. Pancreatology, 22, e11-e12. doi:10.1016/j.pan.2022.06.036
Evaluation of the prognostic role of aspirin and metformin in the ESPAC 4 randomised trial of adjuvant gemcitabine versus gemcitabine plus capecitabine in patients with resected pancreatic cancer
Ponweera, A., Robinson, M., Jackson, R., Halloran, C., Palmer, D., Hackert, T., . . . Ghaneh, P. (2022). Evaluation of the prognostic role of aspirin and metformin in the ESPAC 4 randomised trial of adjuvant gemcitabine versus gemcitabine plus capecitabine in patients with resected pancreatic cancer. Pancreatology, 22, e58. doi:10.1016/j.pan.2022.06.149
Pancreatic cancer-related diabetes mellitus: a clinical perspective
Stott, M., Oldfield, L., Evans, A., Halloran, C., & Costello, E. (2022). Pancreatic cancer-related diabetes mellitus: a clinical perspective. Pancreatology, 22, e63. doi:10.1016/j.pan.2022.06.164
Stratified comparisons of Gemcitabine plus Capecitabine against Gemcitabine alone; further results from the ESPAC-4 trial
Jackson, R., Ghaneh, P., Halloran, C., Palmer, D., Hackert, T., Costello, E., . . . Neoptolemos, J. (2022). Stratified comparisons of Gemcitabine plus Capecitabine against Gemcitabine alone; further results from the ESPAC-4 trial. Pancreatology, 22, e79-e80. doi:10.1016/j.pan.2022.06.206
The Effect of Sampling Methodology upon Pancreatic Cancer Microbiome Communities
Hale, J., Evans, A., Lilley, A., Fine, D., Costello-Goldring, E., Halloran, C., . . . Greenhalf, W. (2022). The Effect of Sampling Methodology upon Pancreatic Cancer Microbiome Communities. Pancreatology, 22, e61. doi:10.1016/j.pan.2022.06.157
United Kingdom Early Detection Initiative (UK-EDI): protocol for establishing a national multicentre cohort of individuals with new-onset diabetes for early detection of pancreatic cancer
Oldfield, L., Stott, M., Hanson, R., Jackson, R. J., Reynolds, W., Chandran-Gorner, V., . . . Costello, E. (2022). United Kingdom Early Detection Initiative (UK-EDI): protocol for establishing a national multicentre cohort of individuals with new-onset diabetes for early detection of pancreatic cancer. BMJ OPEN, 12(10). doi:10.1136/bmjopen-2022-068010
A Multicenter, Randomized, Double-Blinded, Clinical Trial Comparing Cattell-Warren and Blumgart Anastomoses Following Partial Pancreatoduodenectomy: PANasta Trial.
Halloran, C. M., Neoptolemos, J. P., Jackson, R., Platt, K., Psarelli, E. -E., Reddy, S., . . . Ghaneh, P. (2022). A Multicenter, Randomized, Double-Blinded, Clinical Trial Comparing Cattell-Warren and Blumgart Anastomoses Following Partial Pancreatoduodenectomy: PANasta Trial.. Annals of surgery open : perspectives of surgical history, education, and clinical approaches, 3(3), e198. doi:10.1097/as9.0000000000000198
Acute Pancreatitis: Diagnosis and Treatment
Halloran, C. (n.d.). Acute Pancreatitis: Diagnosis and Treatment. Drugs.
Acute Pancreatitis: Diagnosis and Treatment
Szatmary, P., Grammatikopoulos, T., Cai, W., Huang, W., Mukherjee, R., Halloran, C., . . . Sutton, R. (2022). Acute Pancreatitis: Diagnosis and Treatment. DRUGS, 82(12), 1251-1276. doi:10.1007/s40265-022-01766-4
SARS-CoV-2 infection is associated with an increased risk of idiopathic acute pancreatitis but not pancreatic exocrine insufficiency or diabetes: long-term results of the COVIDPAN study
Nayar, M., Varghese, C., Kanwar, A., Siriwardena, A. K., Haque, A. R., Awan, A., . . . Pandanaboyana, S. (2022). SARS-CoV-2 infection is associated with an increased risk of idiopathic acute pancreatitis but not pancreatic exocrine insufficiency or diabetes: long-term results of the COVIDPAN study. GUT, 71(7), 1444-1447. doi:10.1136/gutjnl-2021-326218
EASY-APP: An artificial intelligence model and application for early and easy prediction of severity in acute pancreatitis
Kui, B., Pinter, J., Molontay, R., Nagy, M., Farkas, N., Gede, N., . . . Hegyi, P. (2022). EASY-APP: An artificial intelligence model and application for early and easy prediction of severity in acute pancreatitis. CLINICAL AND TRANSLATIONAL MEDICINE, 12(6). doi:10.1002/ctm2.842
Diagnosis and treatment of exocrine pancreatic insufficiency in chronic pancreatitis: An international expert survey and case vignette study.
de Rijk, F. E. M., van Veldhuisen, C. L., Besselink, M. G., van Hooft, J. E., van Santvoort, H. C., van Geenen, E. J. M., . . . Dutch Pancreatitis Study Group. (2022). Diagnosis and treatment of exocrine pancreatic insufficiency in chronic pancreatitis: An international expert survey and case vignette study.. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 22(4), 457-465. doi:10.1016/j.pan.2022.03.013
Recent advances in understanding pancreatic cancer
Stott, M. C., Oldfield, L., Hale, J., Costello, E., & Halloran, C. M. (n.d.). Recent advances in understanding pancreatic cancer. Faculty Reviews, 11. doi:10.12703/r/11-10
Recent advances in understanding pancreatic cancer.
Stott, M. C., Oldfield, L., Hale, J., Costello, E., & Halloran, C. M. (2022). Recent advances in understanding pancreatic cancer.. Faculty reviews, 11, 9. doi:10.12703/r/11-9
Drain use in pancreatic surgery: Results from an international survey among experts in the field
Pergolini, I., Schorn, S., Goess, R., Novotny, A. R., Ceyhan, G. O., Friess, H., . . . Zerbi, A. (2022). Drain use in pancreatic surgery: Results from an international survey among experts in the field. Surgery. doi:10.1016/j.surg.2021.11.023
Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes
Oldfield, L., Evans, A., Rao, R. G., Jenkinson, C., Purewal, T., Psarelli, E. E., . . . Costello, E. (2022). Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes. EBIOMEDICINE, 75. doi:10.1016/j.ebiom.2021.103802
Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis
Bellomo, G., Rainer, C., Quaranta, V., Astuti, Y., Raymant, M., Boyd, E., . . . Schmid, M. C. (n.d.). Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis. Gut. doi:10.1136/gutjnl-2021-325272
Early infection is an independent risk factor for increased mortality in patients with culture-confirmed infected pancreatic necrosis
Moran, R. A., Halloran, C., Guo, Q., Umapathy, C., Jalaly, N. Y., Jain, S., . . . Singh, V. K. (2022). Early infection is an independent risk factor for increased mortality in patients with culture-confirmed infected pancreatic necrosis. PANCREATOLOGY, 22(1), 67-73. doi:10.1016/j.pan.2021.11.003
2021
P-P25 Hot Axios stent removal following endoscopic pancreatic necrosectomy
Greaves, O., Baron, R., Evans, J., Raraty, M., Mann, K., Kok, K. -S., . . . Dunne, D. (2021). P-P25 Hot Axios stent removal following endoscopic pancreatic necrosectomy. British Journal of Surgery, 108(Supplement_9). doi:10.1093/bjs/znab430.248
Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic
McLean, K. A., Kamarajah, S. K., Chaudhry, D., Gujjuri, R. R., Raubenheimer, K., Trout, I., . . . Wischhusen, S. (2021). Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic. BRITISH JOURNAL OF SURGERY, 108(12), 1448-1464. doi:10.1093/bjs/znab336
The in situ near-total pancreatectomy (LIVOCADO procedure) for end-staged chronic pancreatitis
Baron, R. D., Sheel, A. R. G., Farooq, A., Kleeff, J., Contin, P., Halloran, C. M., & Neoptolemos, J. P. (2021). The in situ near-total pancreatectomy (LIVOCADO procedure) for end-staged chronic pancreatitis. LANGENBECKS ARCHIVES OF SURGERY, 406(8), 2657-2668. doi:10.1007/s00423-021-02107-x
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA
Aughton, K., Elander, N. O., Evans, A., Jackson, R., Campbell, F., Costello, E., . . . Greenhalf, W. (2021). hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. CANCERS, 13(22). doi:10.3390/cancers13225758
Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study
Glasbey, J. C., Ademuyiwa, A., Adisa, A., AlAmeer, E., Arnaud, A. P., Ayasra, F., . . . Aldawbali, M. (2021). Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study. LANCET ONCOLOGY, 22(11), 1507-1517. doi:10.1016/S1470-2045(21)00493-9
Evidence Map of Pancreatic Surgery-A living systematic review with meta-analyses by the International Study Group of Pancreatic Surgery (ISGPS)
Probst, P., Huettner, F. J., Meydan, O., Abu Hilal, M., Adham, M., Barreto, S. G., . . . Diener, M. K. (2021). Evidence Map of Pancreatic Surgery-A living systematic review with meta-analyses by the International Study Group of Pancreatic Surgery (ISGPS). SURGERY, 170(5), 1517-1524. doi:10.1016/j.surg.2021.04.023
Postpancreatectomy Acute Pancreatitis (PPAP)
Marchegiani, G., Barreto, S. G., Bannone, E., Sarr, M., Vollmer, C. M., Connor, S., . . . Shrikhande, S. V. (2021). Postpancreatectomy Acute Pancreatitis (PPAP). Annals of Surgery, Publish Ahead of Print. doi:10.1097/sla.0000000000005226
Abstract 1193: Digital quantification of GATA6 expression from immunohistochemistry is associated with overall survival after surgery for pancreatic cancer in the ESPAC trials
Grant, R. C., Duan, K., Jackson, R., Greenhalf, W., Costello-Goldring, E., Ghaneh, P., . . . Fischer, S. (2021). Abstract 1193: Digital quantification of GATA6 expression from immunohistochemistry is associated with overall survival after surgery for pancreatic cancer in the ESPAC trials. Cancer Research, 81(13_Supplement), 1193. doi:10.1158/1538-7445.am2021-1193
Context specific differences in BRCA2 associated cancer risk
Law, J., Hopley, P., Sarantitis, I., Boughey, A., Pereira, S., Costello, E., . . . Greenhalf, W. (2021). Context specific differences in BRCA2 associated cancer risk. Pancreatology, 21, S62. doi:10.1016/j.pan.2021.05.163
How the COVID-19 pandemic has impacted participation of a pancreatic cancer screening programme
Hopley, P., Sarantitis, I., Edgington, O., Boughey, A., Halloran, C., & Greenhalf, W. (2021). How the COVID-19 pandemic has impacted participation of a pancreatic cancer screening programme. Pancreatology, 21, S81. doi:10.1016/j.pan.2021.05.220
Preoperative diabetes mellitus in patients undergoing pancreatic surgery
Stott, M., Crosby, B., Oldfield, L., Rao, R., Halloran, C. M., & Costello, E. (2021). Preoperative diabetes mellitus in patients undergoing pancreatic surgery. Pancreatology, 21, S53. doi:10.1016/j.pan.2021.05.143
Prognostic impact of CA 19-9 levels in patients with resectable pancreatic cancer who receive adjuvant chemotherapy in randomized controlled trials: A systematic review
Robinson, M., Ponweera, A., Jackson, R., Halloran, C., & Ghaneh, P. (2021). Prognostic impact of CA 19-9 levels in patients with resectable pancreatic cancer who receive adjuvant chemotherapy in randomized controlled trials: A systematic review. Pancreatology, 21, S87. doi:10.1016/j.pan.2021.05.236
Recruitment pathways in the UK early detection initiative (UK-EDI) for pancreatic cancer study
Stott, M., Hanson, R., Oldfield, L., Greenhalf, W., Van Der Meer, R., Allison, L., . . . Costello, E. (2021). Recruitment pathways in the UK early detection initiative (UK-EDI) for pancreatic cancer study. Pancreatology, 21, S109. doi:10.1016/j.pan.2021.05.291
The detoxifying enzyme NQO1 and chemotherapy response prediction in pancreatic cancer
Patel, C., Williams, D., Gana, T., Evans, A., Jackson, R., Campbell, F., . . . Costello, E. (2021). The detoxifying enzyme NQO1 and chemotherapy response prediction in pancreatic cancer. Pancreatology, 21, S69-S70. doi:10.1016/j.pan.2021.05.186
SARS-CoV-2 infection in acute pancreatitis increases disease severity and 30-day mortality: COVID PAN collaborative study
Halloran, C. (n.d.). SARS-CoV-2 infection in acute pancreatitis increases disease severity and 30-day mortality: COVID PAN collaborative study. Gut. doi:10.1136/gutjnl-2020-323364
Severe acute pancreatitis: surgical indications and treatment
Heckler, M., Hackert, T., Hu, K., Halloran, C. M., Buechler, M. W., & Neoptolemos, J. P. (2021). Severe acute pancreatitis: surgical indications and treatment. LANGENBECKS ARCHIVES OF SURGERY, 406(3), 521-535. doi:10.1007/s00423-020-01944-6
The holding temperature of blood during a delay to processing can affect serum and plasma protein measurements
Ashworth, M., Small, B., Oldfield, L., Evans, A., Greenhalf, W., Halloran, C., & Costello, E. (2021). The holding temperature of blood during a delay to processing can affect serum and plasma protein measurements. SCIENTIFIC REPORTS, 11(1). doi:10.1038/s41598-021-85052-5
Preoperative nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pandemic
Glasbey, J. C., Omar, O., Nepogodiev, D., Minaya-Bravo, A., Bankhead-Kendall, B. K., Fiore, M., . . . Scasso, S. (2021). Preoperative nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pandemic. BRITISH JOURNAL OF SURGERY, 108(1), 88-96. doi:10.1093/bjs/znaa051
Cost analysis and outcomes of endoscopic, minimal access and open pancreatic necrosectomy.
Saunders, R., Hughes, F. E., Evans, J. C., Smart, H. L., Ghaneh, P., Ramesh, J., . . . Halloran, C. M. (2021). Cost analysis and outcomes of endoscopic, minimal access and open pancreatic necrosectomy.. Annals of surgery open : perspectives of surgical history, education, and clinical approaches, 2(2), e068. doi:10.1097/as9.0000000000000068
Elective Cancer Surgery in COVID-19–Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study
Glasbey, J. C., & Bhangu, A. (n.d.). Elective Cancer Surgery in COVID-19–Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study. Journal of Clinical Oncology, JCO.20.01933. doi:10.1200/jco.20.01933
Single port retroperitoneal pancreatic necrosectomy for the treatment of extra-pancreatic walled off necrotic collections.
Saunders, R., Neoptolemos, J. P., Hughes, F., Ghaneh, P., & Halloran, C. M. (2021). Single port retroperitoneal pancreatic necrosectomy for the treatment of extra-pancreatic walled off necrotic collections.. Annals of surgery open : perspectives of surgical history, education, and clinical approaches, 2(1), e019. doi:10.1097/as9.0000000000000019
2020
Detecting pancreatic cancer in individuals with new-onset diabetes mellitus: why and how?
Oldfield, L., Rao, R., Purewal, T., Greenhalf, W., Halloran, C., & Costello, E. (2020). Detecting pancreatic cancer in individuals with new-onset diabetes mellitus: why and how?. Pancreatology, 20(8), e2-e3. doi:10.1016/j.pan.2018.10.016
UK–EDI: Detecting Pancreatic Cancer with DM
Oldfield, L., Rao, R. G., Jenkinson, C., Evans, A., Purewal, T., Psarelli, E. E., . . . Costello, E. (2020). UK–EDI: Detecting Pancreatic Cancer with DM. Pancreatology, 20(8), e14. doi:10.1016/j.pan.2020.10.003
GATA6 expression is prognostic after surgical resection of pancreatic cancer: results from the ESPAC trials
Grant, R. C., Duan, K., Jackson, R., Greenhalf, W., Costello-Goldring, E., Ghaneh, P., . . . Fischer, S. (2020). GATA6 expression is prognostic after surgical resection of pancreatic cancer: results from the ESPAC trials. In CANCER RESEARCH Vol. 80. doi:10.1158/1538-7445.PANCA20-PO-005
PANasta Trial: Cattell Warren Versus Blumgart Techniques of Pancreatico-Jejunostomy Following Pancreato-Duodenectomy - A Randomized Double Blind Multi-Center Trial
Halloran, C. M., Neoptolemos, J. P., Jackson, R., Reddy, S., Gomez, D., O'Reilly, D., . . . Ghaneh, P. (2020). PANasta Trial: Cattell Warren Versus Blumgart Techniques of Pancreatico-Jejunostomy Following Pancreato-Duodenectomy - A Randomized Double Blind Multi-Center Trial. In PANCREAS Vol. 49 (pp. 1411). Retrieved from https://www.webofscience.com/
ESPAC-4: A randomized controlled phase III trial of adjuvant gemcitabine (GEM) and capecitabine (CAP) versus gemcitabine in resected pancreatic ductal adenocarcinoma: five year follow up.
Neoptolemos, J., Palmer, D., Gahneh, P., Valle, J., Cunningham, D., Wadsley, J., . . . Buchler, M. (2020). ESPAC-4: A randomized controlled phase III trial of adjuvant gemcitabine (GEM) and capecitabine (CAP) versus gemcitabine in resected pancreatic ductal adenocarcinoma: five year follow up.. Pancreatology, 20, S17-S18. doi:10.1016/j.pan.2020.07.393
ESPAC-5F: Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer.
Sripadam, R., Mukherjee, S., Wadsley, J., Al-Mukhtar, A., Jiao, L. R., Wasan, H. S., . . . Neoptolemos, J. P. (2020). ESPAC-5F: Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38. Retrieved from https://www.webofscience.com/
PANasta Trial: Cattell Warren versus Blumgart techniques of pancreatico-jejunostomy following pancreato-duodenectomy-A double-blinded multi-centered trial, trial results.
Halloran, C., Neoptolemos, J. P., Platt, K., Jackson, R., Reddy, S., Oreily, D., . . . Ghaneh, P. (2020). PANasta Trial: Cattell Warren versus Blumgart techniques of pancreatico-jejunostomy following pancreato-duodenectomy-A double-blinded multi-centered trial, trial results.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38. Retrieved from https://www.webofscience.com/
Prevalence of diabetes mellitus among individuals undergoing pancreatic surgery
Crosby, B., Oldfield, L., Rao, R., Evans, A., Ghaneh, P., Hale, J., . . . Costello, E. (2020). Prevalence of diabetes mellitus among individuals undergoing pancreatic surgery. Pancreatology, 20, S101. doi:10.1016/j.pan.2020.07.172
The holding temperature of blood during a delay to processing can affect serum and plasma protein concentrations.
Small, B., Ashworth, M., Oldfield, L., Greenhalf, W., Halloran, C., & Costello-Goldring, E. (2020). The holding temperature of blood during a delay to processing can affect serum and plasma protein concentrations.. Pancreatology, 20, S120. doi:10.1016/j.pan.2020.07.217
UK Early Detection Initiative (UK-EDI) for Pancreatic Cancer
Oldfield, L., Hanson, R., Greenhalf, W., Meer R., V. D., Alison, L., Christiansen, P., . . . Costello, E. (2020). UK Early Detection Initiative (UK-EDI) for Pancreatic Cancer. Pancreatology, 20, S120-S121. doi:10.1016/j.pan.2020.07.218
Delaying surgery for patients with a previous SARS-CoV-2 infection
Delaying surgery for patients with a previous SARS-CoV-2 infection (2020). BRITISH JOURNAL OF SURGERY, 107(12), E601-E602. doi:10.1002/bjs.12050
Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study
Halloran, C. (2020). Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study. Journal of Clinical Oncology.
Emerging Phenotype of Severe Acute Respiratory Syndrome-Coronavirus 2-associated Pancreatitis.
Szatmary, P., Arora, A., Raraty, M. G. T., Dunne, D. F. J., Baron, R. D., & Halloran, C. M. (2020). Emerging Phenotype of Severe Acute Respiratory Syndrome-Coronavirus 2-associated Pancreatitis. GASTROENTEROLOGY, 159(4), 1551-1554. doi:10.1053/j.gastro.2020.05.069
Prognostic value of 18FDG PET-CT volumetric parameters in the survival prediction of patients with pancreatic cancer
Halloran, C. M. (n.d.). Prognostic value of 18FDG PET-CT volumetric parameters in the survival prediction of patients with pancreatic cancer. Annals of Surgical Oncology. doi:10.1016/j.ejso.2020.02.002
Early detection of pancreatic cancer
Pereira, S. P., Oldfield, L., Ney, A., Hart, P. A., Keane, M. G., Pandol, S. J., . . . Costello, E. (2020). Early detection of pancreatic cancer. The Lancet Gastroenterology and Hepatology, 5(7), 698-710. doi:10.1016/S2468-1253(19)30416-9
Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties.
Barrera, L. N., Evans, A., Lane, B., Brumskill, S., Oldfield, F. E., Campbell, F., . . . Costello, E. (2020). Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties.. Cancer Research, 80(13), 2861-2873. doi:10.1158/0008-5472.can-19-3534
International consensus guidelines on the role of diagnostic endoscopic ultrasound in the management of chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club.
Mel Wilcox, C., Gress, T., Boermeester, M., Masamune, A., Lévy, P., Itoi, T., . . . International (IAP-APA-JPS-EPC) Consensus Guidelines for Chronic Pancreatitis. (2020). International consensus guidelines on the role of diagnostic endoscopic ultrasound in the management of chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club.. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 20(5), 822-827. doi:10.1016/j.pan.2020.05.025
Management of the pancreatic transection plane after left (distal) pancreatectomy: Expert consensus guidelines by the International Study Group of Pancreatic Surgery (ISGPS)
Miao, Y., Lu, Z., Yeo, C. J., Vollmer, C. M. J., Fernandez-del Castillo, C., Ghaneh, P., . . . Buchler, M. W. (2020). Management of the pancreatic transection plane after left (distal) pancreatectomy: Expert consensus guidelines by the International Study Group of Pancreatic Surgery (ISGPS). SURGERY, 168(1), 72-84. doi:10.1016/j.surg.2020.02.018
International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club
Greenhalf, W., Lévy, P., Gress, T., Rebours, V., Brand, R. E., Pandol, S., . . . Neoptolemos, J. (2020). International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club. Pancreatology. doi:10.1016/j.pan.2020.05.011
ESPAC-5F: Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer.
Ghaneh, P., Palmer, D. H., Cicconi, S., Halloran, C., Psarelli, E. E., Rawcliffe, C. L., . . . Neoptolemos, J. P. (2020). ESPAC-5F: Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer.. In Journal of Clinical Oncology Vol. 38 (pp. 4505). American Society of Clinical Oncology (ASCO). doi:10.1200/jco.2020.38.15_suppl.4505
PANasta Trial: Cattell Warren versus Blumgart techniques of pancreatico-jejunostomy following pancreato-duodenectomy—A double-blinded multi-centered trial, trial results.
Halloran, C., Neoptolemos, J. P., Platt, K., Jackson, R., Reddy, S., Oreilly, D., . . . Ghaneh, P. (2020). PANasta Trial: Cattell Warren versus Blumgart techniques of pancreatico-jejunostomy following pancreato-duodenectomy—A double-blinded multi-centered trial, trial results.. Journal of Clinical Oncology, 38(15_suppl), 4619. doi:10.1200/jco.2020.38.15_suppl.4619
Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer
Mahajan, U. M., Goni, E., Langhoff, E., Li, Q., Costello, E., Greenhalf, W., . . . Mayerle, J. (2020). Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. JNCI CANCER SPECTRUM, 4(1). doi:10.1093/jncics/pkz060
ESPAC-5F: Four Arm, Prospective, Multicenter, International Randomized Phase II Trial of Immediate Surgery Compared With Neoadjuvant Gemcitabine Plus Capecitabine (GEMCAP) or FOLFIRINOX or Chemoradiotherapy (CRT) in Patients With Borderline Resectable Pancreatic Cancer
Ghaneh, P., Palmer, D., Cicconi, S., Halloran, C. M., Jackson, R., Rawcliffe, C., . . . Neoptolemos, J. P. (2020). ESPAC-5F: Four Arm, Prospective, Multicenter, International Randomized Phase II Trial of Immediate Surgery Compared With Neoadjuvant Gemcitabine Plus Capecitabine (GEMCAP) or FOLFIRINOX or Chemoradiotherapy (CRT) in Patients With Borderline Resectable Pancreatic Cancer. In PANCREAS Vol. 49 (pp. 1410). Retrieved from https://www.webofscience.com/
PrescrAIP: A Pan-European Study on Current Treatment Regimens of Auto-Immune Pancreatitis
Lanzillotta, M., Vinge-Holmquist, O., Overbeek, K. A., Poulsen, J. L., Demirci, A. F., Macinga, P., . . . Rosendahl, J. (n.d.). PrescrAIP: A Pan-European Study on Current Treatment Regimens of Auto-Immune Pancreatitis. Frontiers in Medicine, 7. doi:10.3389/fmed.2020.00408
2019
Response to Comment on "The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma'' by Niccolo Petrucciani, MD, PhD, FACS, Laura Antolino, MD, Giovanni Moschetta, MD, Giovanni Ramacciato, MD, FACS
Neoptolemos, J. P., Ghaneh, P., Kleeff, J., Halloran, C. M., & Büchler, M. W. (2019). Response to Comment on "The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma'' by Niccolo Petrucciani, MD, PhD, FACS, Laura Antolino, MD, Giovanni Moschetta, MD, Giovanni Ramacciato, MD, FACS. ANNALS OF SURGERY, 270(06), E130-E131. doi:10.1097/SLA.0000000000003371
The Liverpool duodenum-and spleen-preserving near-total pancreatectomy can provide long-term pain relief in patients with end-stage chronic pancreatitis
Sheel, A. R. G., Baron, R. D., Dickerson, L. D., Ghaneh, P., Campbell, F., Raraty, M. G. T., . . . Neoptolemos, J. P. (2019). The Liverpool duodenum-and spleen-preserving near-total pancreatectomy can provide long-term pain relief in patients with end-stage chronic pancreatitis. LANGENBECKS ARCHIVES OF SURGERY, 404(7), 831-840. doi:10.1007/s00423-019-01837-3
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial
Jones, R. P., Psarelli, E. -E., Jackson, R., Ghaneh, P., Halloran, C. M., Palmer, D. H., . . . Millat, B. (2019). Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. JAMA SURGERY, 154(11), 1038-1048. doi:10.1001/jamasurg.2019.3337
Natural history of SPINK1 germline mutation related-pancreatitis
Muller, N., Sarantitis, I., Rouanet, M., de Mestier, L., Halloran, C. M., & Greenhalf, W. (2019). Natural history of SPINK1 germline mutation related-pancreatitis. EBioMedicine, 48, 581-591. doi:10.1016/j.ebiom.2019.09.032
Blood levels of adiponectin and IL-1Ra could facilitate earlier detection of PDAC by distinguishing individuals with type 3c diabetes from those with type 2 diabetes
Oldfield, L., Rao, R., Purewal, T., Greenhalf, W., Halloran, C., & Costello, E. (2019). Blood levels of adiponectin and IL-1Ra could facilitate earlier detection of PDAC by distinguishing individuals with type 3c diabetes from those with type 2 diabetes. Pancreatology, 19, S3. doi:10.1016/j.pan.2019.05.004
PDAC-associated fibroblasts are less responsive to an anti-fibrotic stimulus and more responsive to a positive regulator of fibroblast activation than normal activated fibroblasts
Barrera, L. N., Evans, A., Lane, B., Brumskill, S., Oldfield, F., Campbell, F., . . . Costello, E. (2019). PDAC-associated fibroblasts are less responsive to an anti-fibrotic stimulus and more responsive to a positive regulator of fibroblast activation than normal activated fibroblasts. Pancreatology, 19, S158. doi:10.1016/j.pan.2019.05.423
Patterns of cancers in families with confirmed pathogenic BRCA2 mutations
Law, J., Sarantitis, I., Boughly, A., Periera, S., Costello, E., Halloran, C., & Greenhalf, W. (2019). Patterns of cancers in families with confirmed pathogenic BRCA2 mutations. Pancreatology, 19, S66. doi:10.1016/j.pan.2019.05.169
A systematic review and meta-analysis of metal versus plastic stents for drainage of pancreatic fluid collections: metal stents are advantageous
Saunders, R., Ramesh, J., Cicconi, S., Evans, J., Yip, V. S., Raraty, M., . . . Halloran, C. (2019). A systematic review and meta-analysis of metal versus plastic stents for drainage of pancreatic fluid collections: metal stents are advantageous. SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 33(5), 1412-1425. doi:10.1007/s00464-018-6416-5
Pancreas-specific plasma amylase for assessment and diagnosis of chronic pancreatitis: New insights on an old topic
Olesen, S. S., Krarup, H., Poulsen, J. L., Christensen, J. H., Sheel, A. R. G., Sutton, R., . . . Drewes, A. M. (2019). Pancreas-specific plasma amylase for assessment and diagnosis of chronic pancreatitis: New insights on an old topic. United European Gastroenterology Journal. doi:10.1177/2050640619846011
Tumour stage and resection margin status are independent survival factors following partial pancreatoduodenectomy for duodenal adenocarcinoma
Mann, K., Gilbert, T., Cicconi, S., Jackson, R., Whelan, P., Campbell, F., . . . Ghaneh, P. (2019). Tumour stage and resection margin status are independent survival factors following partial pancreatoduodenectomy for duodenal adenocarcinoma. LANGENBECKS ARCHIVES OF SURGERY, 404(4), 439-449. doi:10.1007/s00423-019-01779-w
The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma
Ghaneh, P., Kleeff, J., Halloran, C. M., Raraty, M., Jackson, R., Melling, J., . . . Smith, C. (2019). The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 269(03), 520-529. doi:10.1097/SLA.0000000000002557
Identification of Cystic Lesions by Secondary Screening of Familial Pancreatic Cancer (FPC) Kindreds Is Not Associated with the Stratified Risk of Cancer.
Sheel, A. R. G., Harrison, S., Sarantitis, I., Nicholson, J. A., Hanna, T., Grocock, C., . . . Greenhalf, W. (2019). Identification of Cystic Lesions by Secondary Screening of Familial Pancreatic Cancer (FPC) Kindreds Is Not Associated with the Stratified Risk of Cancer.. The American Journal of Gastroenterology (Elsevier), 114(1), 155-164. doi:10.1038/s41395-018-0395-y
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma (PDAC) in the ESPAC-4 Randomized Adjuvant Chemotherapy Trial
Neoptolemos, J. P., Jones, R. P., Psarelli, E. E., Jackson, R., Ghaneh, P., Halloran, C. M., . . . Buechler, M. W. (2019). Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma (PDAC) in the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. In PANCREAS Vol. 48 (pp. 1497-1498). Retrieved from https://www.webofscience.com/
hENT1 RNA and Protein in Combination May Act as Predictive Biomarkers for Survival for Patients Treated With Adjuvant Gemcitabine in Pancreatic Cancer
Hale, J., Evans, A., Aughton, K., Elander, N. O., Ghaneh, P., Neoptolemos, J. P., . . . Greenhalf, W. (2019). hENT1 RNA and Protein in Combination May Act as Predictive Biomarkers for Survival for Patients Treated With Adjuvant Gemcitabine in Pancreatic Cancer. In PANCREAS Vol. 48 (pp. 1436-1437). Retrieved from https://www.webofscience.com/
2018
Immune Cell and Stromal Signature Associated with Progression-free Survival of Patients with Resected Pancreatic Ductal Adenocarcinoma
Mahajan, U. M., Langhoff, E., Goni, E., Costello, E., Greenhalf, W., Halloran, C. M., . . . Mayerle, J. (2018). Immune Cell and Stromal Signature Associated with Progression-free Survival of Patients with Resected Pancreatic Ductal Adenocarcinoma. Gastroenterology, 155(05), 1625-1639.E2. doi:10.1053/j.gastro.2018.08.009
Role of Radiological Imaging in the Diagnosis and Characterization of Pancreatic Cystic Lesions: A Systematic Review
Mohamed, E., Jackson, R., Halloran, C. M., & Ghaneh, P. (2018). Role of Radiological Imaging in the Diagnosis and Characterization of Pancreatic Cystic Lesions: A Systematic Review. PANCREAS, 47(9), 1055-1064. doi:10.1097/MPA.0000000000001134
The diagnostic value of Rosemont and Japanese diagnostic criteria for 'indeterminate', 'suggestive', 'possible' and 'early' chronic pancreatitis
Sheel, A. R. G., Baron, R. D., Sarantitis, I., Ramesh, J., Ghaneh, P., Raraty, M. G. T., . . . Neoptolemos, J. P. (2018). The diagnostic value of Rosemont and Japanese diagnostic criteria for 'indeterminate', 'suggestive', 'possible' and 'early' chronic pancreatitis. PANCREATOLOGY, 18(7), 774-784. doi:10.1016/j.pan.2018.08.002
Mucinous Tumours of the Pancreas
Rao, R. G., Healey, P., & Halloran, C. M. (2018). Mucinous Tumours of the Pancreas. In Surgical Diseases of the Pancreas and Biliary Tree (pp. 311-332). Springer Singapore. doi:10.1007/978-981-10-8755-4_12
18FDG PET/CT improves staging of small ≤2 cm pancreatic tumours
Mohamed, E., Sanghera, B., Wong, W., Halloran, C., & Ghaneh, P. (2018). 18FDG PET/CT improves staging of small ≤2 cm pancreatic tumours. HPB, 20, S560. doi:10.1016/j.hpb.2018.06.2024
Does tumour SUVmax predict adverse prognostic features in patients with pancreatic cancer?
Mohamed, E., Sanghera, B., Wong, W., Halloran, C., & Ghaneh, P. (2018). Does tumour SUVmax predict adverse prognostic features in patients with pancreatic cancer?. HPB, 20, S771. doi:10.1016/j.hpb.2018.06.2499
Alcohol excess and continued smoking are risk factors for progression from minimal change chronic pancreatitis to established chronic pancreatitis
Sheel, A., Baron, R., Ramesh, J., Ghaneh, P., Raraty, M., Yip, V., . . . Neoptolemos, J. (2018). Alcohol excess and continued smoking are risk factors for progression from minimal change chronic pancreatitis to established chronic pancreatitis. Pancreatology, 18(4), S103-S104. doi:10.1016/j.pan.2018.05.279
An endoscopic approach for pancreatic necrosis may reduce length of stay compared to minimal access surgery
Saunders, R., Ramesh, J., Griffin, R., McCready, R., Hughes, F., Evans, J., . . . Halloran, C. (2018). An endoscopic approach for pancreatic necrosis may reduce length of stay compared to minimal access surgery. Pancreatology, 18(4), S93-S94. doi:10.1016/j.pan.2018.05.253
Differentiation of autoimmune pancreatitis from pancreatic cancer remains challenging
Dickerson, L. D., Farooq, A., Bano, F., Kleeff, J., Halloran, C., Raraty, M., . . . Yip, V. S. (2018). Differentiation of autoimmune pancreatitis from pancreatic cancer remains challenging. Pancreatology, 18(4), S117. doi:10.1016/j.pan.2018.05.314
Disease associated fibroblasts from various pancreatic disorders exhibit subtype specific genetic profile
Barrera, L., Evans, A., Lane, B., Brumskill, S., Oldfield, F., Campbell, F., . . . Costello, E. (2018). Disease associated fibroblasts from various pancreatic disorders exhibit subtype specific genetic profile. Pancreatology, 18(4), S94. doi:10.1016/j.pan.2018.05.254
Enhanced Recovery After Surgery (ERAS) reduces the incidence of Delayed Gastric Emptying (DGE) following Pancreaticoduodenectomy
Sheel, A., Exarchou, K., Baron, R., Akintunde, V., Garry, J., Whelan, P., . . . Yip, V. (2018). Enhanced Recovery After Surgery (ERAS) reduces the incidence of Delayed Gastric Emptying (DGE) following Pancreaticoduodenectomy. Pancreatology, 18(4), S84-S85. doi:10.1016/j.pan.2018.05.227
Pre-operative clinical status predicts a successful enhanced recovery programme for pancreaticoduodenectomy: A single tertiary centre experience
Exarchou, K., Yip, V., Thompson, P., Kleeff, J., Garry, J., Ghaneh, P., . . . Raraty, M. (2018). Pre-operative clinical status predicts a successful enhanced recovery programme for pancreaticoduodenectomy: A single tertiary centre experience. Pancreatology, 18(4), S162-S163. doi:10.1016/j.pan.2018.05.439
Single incision laparoscopic surgery flank necrosectomy: A novel approach to extra-pancreatic walled off necrosis
Saunders, R., Evans, J., McCready, R., Hughes, F., Raraty, M., Yip, V., . . . Halloran, C. (2018). Single incision laparoscopic surgery flank necrosectomy: A novel approach to extra-pancreatic walled off necrosis. Pancreatology, 18(4), S170. doi:10.1016/j.pan.2018.05.459
The SPINK1 p.N34S variant is associated with early onset idiopathic recurrent acute pancreatitis progressing to chronic disease, but not with more rapid progression to other disease outcomes such as diabetes mellitus
Sarantitis, I., Sheel, A., Nicholson, J., McCarthy, E., Howard, E., Baron, R., . . . Greenhalf, W. (2018). The SPINK1 p.N34S variant is associated with early onset idiopathic recurrent acute pancreatitis progressing to chronic disease, but not with more rapid progression to other disease outcomes such as diabetes mellitus. Pancreatology, 18(4), S174-S175. doi:10.1016/j.pan.2018.05.471
The development of a Rapid Access Nurse Clinic (RANC) for benign and malignant pancreato biliary disease
Whelan, P., Garry, J., Hughes, F., McCready, R., Raraty, M., Sutton, R., . . . Halloran, C. (2018). The development of a Rapid Access Nurse Clinic (RANC) for benign and malignant pancreato biliary disease. Pancreatology, 18(4), S163. doi:10.1016/j.pan.2018.05.440
The influence of demographics, risk and smoking status on attendance for pancreatic cancer screening
Law, J., Sarantitis, I., Sheel, A., Costello, E., Hamady, Z., Guru, A., . . . Greenhalf, W. (2018). The influence of demographics, risk and smoking status on attendance for pancreatic cancer screening. Pancreatology, 18(4), S154-S155. doi:10.1016/j.pan.2018.05.416
Towards earlier detection of PDAC: Validation of a biomarker panel for the identification of type 3c diabetes among individuals newly diagnosed with type 2 diabetes
Oldfield, L., Rao, R., Purewal, T., Neoptolemos, J. P., Greenhalf, W., Halloran, C., & Costello, E. (2018). Towards earlier detection of PDAC: Validation of a biomarker panel for the identification of type 3c diabetes among individuals newly diagnosed with type 2 diabetes. Pancreatology, 18(4), S72. doi:10.1016/j.pan.2018.05.194
Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy
Elander, N. O., Aughton, K., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., . . . Canc, E. S. G. P. (2018). Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. British Journal of Cancer, 118, 1084-1088. doi:10.1038/s41416-018-0005-1
Arterial Resection in Pancreatic Cancer
Dunne, D. F. J., Kleeff, J., Yip, V. S., Halloran, C., Ghaneh, P., & Neoptolemos, J. P. (2018). Arterial Resection in Pancreatic Cancer. In Pancreatic Cancer (pp. 1089-1104). Springer New York. doi:10.1007/978-1-4939-7193-0_72
Laparoscopic Staging in Patients with Newly Diagnosed Pancreatic Cancer
Gilbert, T., Baron, R., Ghaneh, P., & Halloran, C. (2018). Laparoscopic Staging in Patients with Newly Diagnosed Pancreatic Cancer. In Pancreatic Cancer (pp. 753-769). Springer New York. doi:10.1007/978-1-4939-7193-0_80
Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predict survival in pancreatic cancer.
Elander, N. O., Aughton, K., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., . . . Greenhalf, W. (2018). Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predict survival in pancreatic cancer.. British Journal of Cancer, 118(7), 947-954. doi:10.1038/s41416-018-0004-2
Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.
Halloran, C. M. (n.d.). Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.. JNCI: Journal of the National Cancer Institute.
Minimally Invasive Debridement and Lavage of Necrotizing Pancreatitis
Saunders, R., Raraty, M. G. T., Halloran, C., & Neoptolemos, J. P. (2018). Minimally Invasive Debridement and Lavage of Necrotizing Pancreatitis. In Unknown Book (pp. 283-288). Wiley. doi:10.1002/9781119188421.ch31
Cytoplasmic HuR Status Predicts Disease-Free Survival in Resected Pancreatic Cancer: A Post-Hoc Analysis from the International Multi-Institutional Phase III ESPAC-3 Clinical Trial
Halloran, C. M. (2018). Cytoplasmic HuR Status Predicts Disease-Free Survival in Resected Pancreatic Cancer: A Post-Hoc Analysis from the International Multi-Institutional Phase III ESPAC-3 Clinical Trial. Annals of Surgery, 267(2), 364-369. doi:10.1097/SLA.0000000000002088
PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality (18)fluorine-2-fluoro-2-deoxy-D-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer
Ghaneh, P., Hanson, R., Titman, A., Lancaster, G., Plumpton, C., Lloyd-Williams, H., . . . Neoptolemos, J. P. (2018). PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality <SUP>18</SUP>fluorine-2-fluoro-2-deoxy-D-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer. HEALTH TECHNOLOGY ASSESSMENT, 22(7), 1-+. doi:10.3310/hta22070
Pancreatic Cancer and FOLFIRINOX: Should We Resect All Responders?
Neoptolemos, J. P., Halloran, C. M., Ghaneh, P., & Kleeff, J. (2018). Pancreatic Cancer and FOLFIRINOX: Should We Resect All Responders?. Ann Surg, 267(2), e35-e36. doi:10.1097/SLA.0000000000002026
2017
Detecting Pancreatic Cancer Earlier: Identifying Type 3c Diabetes in Individuals Newly Diagnosed With Type 2 Diabetes
Oldfield, L., Rao, R., Purewal, T., Neoptolemos, J. P., Halloran, C. M., Greenhalf, W., & Costello, E. (2017). Detecting Pancreatic Cancer Earlier: Identifying Type 3c Diabetes in Individuals Newly Diagnosed With Type 2 Diabetes. In PANCREAS Vol. 46 (pp. 1425). Retrieved from https://www.webofscience.com/
Nrf2 in Pancreatic Cancer Chemotherapy Response and the Use of Brusatol as a Chemotherapeutic Agent
Williams, D., Gana, T., Sivapalan, L., Butler, O., Jackson, R., Perez-Mancera, P., . . . Costello, E. (2017). Nrf2 in Pancreatic Cancer Chemotherapy Response and the Use of Brusatol as a Chemotherapeutic Agent. In PANCREAS Vol. 46 (pp. 1443). Retrieved from http://gateway.webofknowledge.com/
The Prevalence of Diabetes Mellitus is Significantly Higher for Patients Undergoing Surgery for Pancreatic Ductal Adenocarcinoma Compared to Surgery for Other Pancreatic Pathologies
Rao, R. G., Costello, E., Halloran, C. M., Oldfield, L., Greenhalf, W., Ghaneh, P., . . . Mann, K. (2017). The Prevalence of Diabetes Mellitus is Significantly Higher for Patients Undergoing Surgery for Pancreatic Ductal Adenocarcinoma Compared to Surgery for Other Pancreatic Pathologies. In PANCREAS Vol. 46 (pp. 1403-1404). Retrieved from https://www.webofscience.com/
Partial pancreatoduodenectomy versus duodenum-preserving pancreatic head resection in chronic pancreatitis: the multicentre, randomised, controlled, double-blind ChroPac trial
Diener, M. K., Hüttner, F. J., Kieser, M., Knebe, P., Dörr-Harim, C., Distler, M., . . . Hackert, T. (2017). Partial pancreatoduodenectomy versus duodenum-preserving pancreatic head resection in chronic pancreatitis: the multicentre, randomised, controlled, double-blind ChroPac trial. The Lancet, 390(10099), 1027-1037. doi:10.1016/S0140-6736(17)31960-8
Guidelines for the understanding and management of pain in chronic pancreatitis
Drewes, A. M., Bouwense, S. A. W., Campbell, C. M., Ceyhan, G. O., Delhaye, M., Demir, I. E., . . . Yadav, D. (2017). Guidelines for the understanding and management of pain in chronic pancreatitis. Pancreatology, 17(05), 720-731. doi:10.1016/j.pan.2017.07.006
A comprehensive prognostic signature based on interaction of immune cell infiltration with stromal composition for resected pancreatic ductal adenocarcinoma
Mahajan, U. M., Langhoff, E., Costello, E., Greenhalf, W., Halloran, C., Beyer, G., . . . Mayerle, J. (2017). A comprehensive prognostic signature based on interaction of immune cell infiltration with stromal composition for resected pancreatic ductal adenocarcinoma. Pancreatology, 17(3), S34. doi:10.1016/j.pan.2017.05.107
Cytokines as potential biomarkers for distinguishing patients with pancreatic cancer and type 2 diabetes mellitus
Rao, R. G., Oldfield, L., Evans, A., Sivapalan, L., Schuler, P., Purewal, T., . . . Costello, E. (2017). Cytokines as potential biomarkers for distinguishing patients with pancreatic cancer and type 2 diabetes mellitus. Pancreatology, 17(3), S33. doi:10.1016/j.pan.2017.05.103
Duodenum-preserving pancreatic head resection reduces long term pain scores and opioid analgesic use in chronic pancreatitis
Dickerson, L., Baron, R., Sheel, A., Halloran, C., Ghaneh, P., Raraty, M., . . . Neoptolemos, J. (2017). Duodenum-preserving pancreatic head resection reduces long term pain scores and opioid analgesic use in chronic pancreatitis. Pancreatology, 17(3), S90. doi:10.1016/j.pan.2017.05.284
Missed pancreatic ductal adenocarcinoma (PDAC) in Hereditary Pancreatitis (HP) kindreds indicate the importance of a systematic approach to secondary screening
Sheel, A., Harrison, S., Sarantitis, I., Nicholson, J., Halloran, C., Raraty, M., . . . Greenhalf, W. (2017). Missed pancreatic ductal adenocarcinoma (PDAC) in Hereditary Pancreatitis (HP) kindreds indicate the importance of a systematic approach to secondary screening. Pancreatology, 17(3), S66. doi:10.1016/j.pan.2017.05.209
Modelling the Tumour Microenvironment in Pancreatic Ductal Adenocarcinoma
Brumskill, S., Barrera, L., Campbell, F., Halloran, C., Neoptolemos, J., Sutton, R., . . . Costello, E. (2017). Modelling the Tumour Microenvironment in Pancreatic Ductal Adenocarcinoma. Pancreatology, 17(3), S4. doi:10.1016/j.pan.2017.05.011
OC-079 Role of metal vs plastic stents for endoscopic ultrasound guided drainage of peri-pancreatic fluid collections: a systematic review and meta-analysis
Ramesh, J., Saunders, R., Cicconi, S., Sutton, R., Neoptolemos, J., & Halloran, C. (2017). OC-079 Role of metal vs plastic stents for endoscopic ultrasound guided drainage of peri-pancreatic fluid collections: a systematic review and meta-analysis. Gut, 66(Suppl 2), a42. doi:10.1136/gutjnl-2017-314472.79
Risk independence for the identification of cystic lesions in Familial Pancreatic Cancer (FPC) kindreds
Sheel, A., Harrison, S., Sarantitis, I., Nicholson, J., Halloran, C., Raraty, M., . . . Greenhalf, W. (2017). Risk independence for the identification of cystic lesions in Familial Pancreatic Cancer (FPC) kindreds. Pancreatology, 17(3), S68. doi:10.1016/j.pan.2017.05.215
Role of metal vs plastic stents for endoscopic ultrasound guided drainage of peri-pancreatic fluid collections: A systematic review and meta-analysis
Saunders, R., Ramesh, J., Cicconi, S., Sutton, R., Neoptolemos, J., & Halloran, C. (2017). Role of metal vs plastic stents for endoscopic ultrasound guided drainage of peri-pancreatic fluid collections: A systematic review and meta-analysis. Pancreatology, 17(3), S84. doi:10.1016/j.pan.2017.05.265
Symptom and diabetes onset in idiopathic pancreatitis: The role of SPINK1 p.N34S mutation
Sarantitis, I., Sheel, A., Halloran, C., Mountford, R., Harrison, S., Monk, T., . . . Greenhalf, W. (2017). Symptom and diabetes onset in idiopathic pancreatitis: The role of SPINK1 p.N34S mutation. Pancreatology, 17(3), S104. doi:10.1016/j.pan.2017.05.327
USAGE OF TRANSMURAL METAL STENTS FOR ENDOSCOPIC ULTRASOUND GUIDED DRAINAGE OF PSEUDOCYSTS MAY LEAD TO LOWER REINTERVENTION RATES
Ramesh, J., Saunders, R., Evans, J., Ghaneh, P., Raraty, M., Yip, V., . . . Halloran, C. (2017). USAGE OF TRANSMURAL METAL STENTS FOR ENDOSCOPIC ULTRASOUND GUIDED DRAINAGE OF PSEUDOCYSTS MAY LEAD TO LOWER REINTERVENTION RATES. In GUT Vol. 66 (pp. A276). doi:10.1136/gutjnl-2017-314472.538
Usage of transmural metal stents for endoscopic ultrasound guided drainage of pseudocysts may lead to lower reintervention rates
Ramesh, J., Saunders, R., Evans, J., Ghaneh, P., Raraty, M., Yip, V., . . . Halloran, C. (2017). Usage of transmural metal stents for endoscopic ultrasound guided drainage of pseudocysts may lead to lower reintervention rates. Pancreatology, 17(3), S84. doi:10.1016/j.pan.2017.05.266
A comprehensive prognostic signature based on interaction of immune cell infiltration with stromal composition for resected pancreatic ductal adenocarcinoma
Mahajan, U. M., Langhoff, E., Costello, E., Greenhalf, W., Halloran, C., Beyer, G., . . . Mayerle, J. (n.d.). A comprehensive prognostic signature based on interaction of immune cell infiltration with stromal composition for resected pancreatic ductal adenocarcinoma. Zeitschrift für Gastroenterologie, 55(05), e1-e27. doi:10.1055/s-0037-1603060
Pancreatic Anastomosis After Pancreatoduodenectomy: A Position Statement By The International Study Group Of Pancreatic Surgery (ISGPS)
Halloran, C. M. (2017). Pancreatic Anastomosis After Pancreatoduodenectomy:A Position Statement By The International Study Group Of Pancreatic Surgery (ISGPS). Surgery, 161(5), 1221-1234. doi:10.1016/j.surg.2016.11.021
Beyond ESPAC-4: better surgery and systemic therapy
Psarelli, E. E., Jackson, R., Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Halloran, C. M., & Buechler, M. W. (2017). Beyond ESPAC-4: better surgery and systemic therapy. LANCET, 389(10078), 1517-1518. doi:10.1016/S0140-6736(17)30947-9
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M., . . . Büchler, M. W. (2017). Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.. Lancet (London, England), 389(10073), 1011-1024. doi:10.1016/s0140-6736(16)32409-6
2016
Chemotherapy and radiotherapy for pancreatic cancer
Halloran, C. M., Oldfield, F. E., & Neoptolemos, J. P. (2017). Chemotherapy and radiotherapy for pancreatic cancer. In Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set (pp. 1032-1041.e3). Elsevier. doi:10.1016/b978-0-323-34062-5.00068-6
Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients
Rizzato, C., Campa, D., Talar-Wojnarowska, R., Halloran, C., Kupcinskas, J., Butturini, G., . . . Canzian, F. (2016). Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. Carcinogenesis, 37(10), 957-964. doi:10.1093/carcin/bgw080
The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer
Kleeff, J., Costello, E., Jackson, R., Halloran, C., Greenhalf, W., Ghaneh, P., . . . Neoptolemos, J. P. (2016). The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer. BRITISH JOURNAL OF CANCER, 115(7), 887-894. doi:10.1038/bjc.2016.277
Cathepsin B mediates tumor-stroma cross-talk in pancreatic cancer but its expression levels do not affect overall patient survival
Langhoff, E., Mahajan, U. M., Costello, E., Greenhalf, W., Halloran, C., Weiss, F. -U., . . . Mayerle, J. (2016). Cathepsin B mediates tumor-stroma cross-talk in pancreatic cancer but its expression levels do not affect overall patient survival. Pancreatology, 16(3), S26. doi:10.1016/j.pan.2016.05.091
Changes in expression of the subunits of Ribonucleotide Reductase induce gemcitabine resistance in the Suit-2 Pancreatic Cancer Cell Line
Mann, K., Melling, J., Costello, E., Halloran, C., Ghaneh, P., & Greenhalf, W. (2016). Changes in expression of the subunits of Ribonucleotide Reductase induce gemcitabine resistance in the Suit-2 Pancreatic Cancer Cell Line. Pancreatology, 16(3), S27-S28. doi:10.1016/j.pan.2016.05.095
Combined analysis of cytidine deaminase mRNA transcript expression with hENT1 protein expression on tissue microarrays from the ESPAC-3 trial helps predict patient survival with gemcitabine treatment
Aughton, K., Elander, N., Palmer, D., Cox, T., Campbell, F., Garner, E., . . . Greenhalf, W. (2016). Combined analysis of cytidine deaminase mRNA transcript expression with hENT1 protein expression on tissue microarrays from the ESPAC-3 trial helps predict patient survival with gemcitabine treatment. Pancreatology, 16(3), S30. doi:10.1016/j.pan.2016.05.104
Diabetes mellitus and tobacco smoking independently increase the risk of developing pancreatic cancer in hereditary pancreatitis (HP) in individuals from the European register for hereditary pancreatitis and pancreatic cancer (EUROPAC)
Sheel, A., Costello, E., Neoptolemos, J., Harrison, S., Lerch, M., Mayerle, J., . . . Greenhalf, W. (2016). Diabetes mellitus and tobacco smoking independently increase the risk of developing pancreatic cancer in hereditary pancreatitis (HP) in individuals from the European register for hereditary pancreatitis and pancreatic cancer (EUROPAC). Pancreatology, 16(3), S88. doi:10.1016/j.pan.2016.05.297
Duodenum-and spleen-preserving total pancreatectomy (DPSPTP) for end-staged chronic pancreatitis: 20 years' experience from a single pancreatic centre
Sheel, A., Baron, R., Halloran, C., Ghaneh, P., Raraty, M., Sutton, R., . . . Neoptolemos, J. (2016). Duodenum-and spleen-preserving total pancreatectomy (DPSPTP) for end-staged chronic pancreatitis: 20 years' experience from a single pancreatic centre. Pancreatology, 16(3), S86-S87. doi:10.1016/j.pan.2016.05.292
Identification of malignant transformation within pancreatic IPMN: A systematic review and meta-analyses
Halloran, C., Jackson, R., Gilbert, T., Psarelli, E., Cox, T., Sutton, R., . . . Neoptolemos, J. (2016). Identification of malignant transformation within pancreatic IPMN: A systematic review and meta-analyses. Pancreatology, 16(3), S99. doi:10.1016/j.pan.2016.05.333
Identification of novel signalling pathways dysregulated in pancreatic cancer-associated fibroblasts
Barrera, L., Lane, B., Brumskill, S., Oldfield, F., Lamond, R., Wilkinson, L., . . . Costello, E. (2016). Identification of novel signalling pathways dysregulated in pancreatic cancer-associated fibroblasts. Pancreatology, 16(3), S31. doi:10.1016/j.pan.2016.05.106
Misdiagnosis of chronic pancreatitis (CP) in a regional pancreas centre
Sheel, A., Halloran, C., Ghaneh, P., Kleeff, J., Raraty, M., Sutton, R., . . . Neoptolemos, J. (2016). Misdiagnosis of chronic pancreatitis (CP) in a regional pancreas centre. Pancreatology, 16(3), S94-S95. doi:10.1016/j.pan.2016.05.318
Outcome and survival in a single centre experience of 58 patients with duodenal adenocarcinoma undergoing pancreato-duodenectomy
Mann, K., Gilbert, T., Whelan, P., Yip, V., Halloran, C., Raraty, M., . . . Ghaneh, P. (2016). Outcome and survival in a single centre experience of 58 patients with duodenal adenocarcinoma undergoing pancreato-duodenectomy. Pancreatology, 16(3), S98-S99. doi:10.1016/j.pan.2016.05.332
PET-PANC: Multi-centre prospective diagnostic accuracy and clinical value study of PET/CT in the diagnosis and management of pancreatic cancer
Ghaneh, P., Wong, W. L., Titman, A., Plumpton, C., Vinjamuri, S., Johnson, C., . . . Neoptolemos, J. (2016). PET-PANC: Multi-centre prospective diagnostic accuracy and clinical value study of PET/CT in the diagnosis and management of pancreatic cancer. Pancreatology, 16(3), S91. doi:10.1016/j.pan.2016.05.306
Targeted limiting dilution next-generation sequencing of p53 for the molecular detection of pancreatic ductal adenocarcinoma using pancreatic juice collected from the duodenum
Yan, L., Nicholson, J., Sheel, A., Harrison, S., Costello, E., Hanna, T., . . . Greenhalf, W. (2016). Targeted limiting dilution next-generation sequencing of p53 for the molecular detection of pancreatic ductal adenocarcinoma using pancreatic juice collected from the duodenum. Pancreatology, 16(3), S33. doi:10.1016/j.pan.2016.05.112
The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma
Kleeff, J., Costello, E., Jackson, R., Halloran, C., Greenhalf, W., Ghaneh, P., . . . Neoptolemos, J. P. (2016). The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Pancreatology, 16(3), S67. doi:10.1016/j.pan.2016.05.228
PET-PANC: Multi-centre prospective diagnostic accuracy and clinical value trial of FDG PET/CT in the diagnosis and management of suspected pancreatic cancer
Ghaneh, P., Wong, W. L., Titman, A., Plumpton, C., Vinjamuri, S., Johnson, C., . . . Neoptolemos, J. P. (2016). PET-PANC: Multi-centre prospective diagnostic accuracy and clinical value trial of FDG PET/CT in the diagnosis and management of suspected pancreatic cancer. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34. doi:10.1200/JCO.2016.34.15_suppl.4008
PET-PANC: Multi-centre prospective diagnostic accuracy and clinical value trial of FDG PET/CT in the diagnosis and management of suspected pancreatic cancer.
Ghaneh, P., Wong, W. L., Titman, A., Plumpton, C., Vinjamuri, S., Johnson, C., . . . Neoptolemos, J. P. (2016). PET-PANC: Multi-centre prospective diagnostic accuracy and clinical value trial of FDG PET/CT in the diagnosis and management of suspected pancreatic cancer.. In Journal of Clinical Oncology Vol. Vol 34. Chicago: American Society of Clinical Oncology.
Gemcitabine-loaded and antibody-tagged superparamagnetic iron oxide nanoparticles as targeted drug vehicles in pancreatic cancer cell lines
Nandi, S., Sykes, P. D., Hasan, E., Rubbi, C., Barrow, M., Neoptolemos, J. P., . . . Halloran, C. M. (2016). Gemcitabine-loaded and antibody-tagged superparamagnetic iron oxide nanoparticles as targeted drug vehicles in pancreatic cancer cell lines. HPB, 18, e776. doi:10.1016/j.hpb.2016.01.306
Management and Outcome of 64 Patients with Pancreatic Serous Cystic Neoplasms
Gomatos, I. P., Halloran, C., Ghaneh, P., Raraty, M., Polydoros, F., Campbell, F., . . . Neoptolemos, J. P. (2016). Management and Outcome of 64 Patients with Pancreatic Serous Cystic Neoplasms. DIGESTIVE SURGERY, 33(3), 203-212. doi:10.1159/000442094
PANasta Trial; Cattell Warren versus Blumgart techniques of panreatico-jejunostomy following pancreato-duodenectomy: Study protocol for a randomized controlled trial
Halloran, C. M., Platt, K., Gerard, A., Polydoros, F., O'Reilly, D. A., Gomez, D., . . . Ghaneh, P. (2016). PANasta Trial; Cattell Warren versus Blumgart techniques of panreatico-jejunostomy following pancreato-duodenectomy: Study protocol for a randomized controlled trial. TRIALS, 17. doi:10.1186/s13063-015-1144-9
Arterial Resection in Pancreatic Cancer
Dunne, D. F. J., Kleeff, J., Yip, V. S., Halloran, C., Ghaneh, P., & Neoptolemos, J. P. (2016). Arterial Resection in Pancreatic Cancer. In Pancreatic Cancer (pp. 1-16). Springer New York. doi:10.1007/978-1-4939-6631-8_72-1
Laparoscopic Staging in Patients with Newly Diagnosed Pancreatic Cancer
Gilbert, T., Baron, R., Ghaneh, P., & Halloran, C. (2016). Laparoscopic Staging in Patients with Newly Diagnosed Pancreatic Cancer. In Pancreatic Cancer (pp. 1-17). Springer New York. doi:10.1007/978-1-4939-6631-8_80-1
Outcomes From Minimal Access Retroperitoneal and Open Pancreatic Necrosectomy in 394 Patients With Necrotizing Pancreatitis
Gomatis, I., Halloran, C. M., Ghaneh, P., Raraty, M., Polydoros, F., Evans, J. C., . . . Neoptolemos, J. P. (2016). Outcomes From Minimal Access Retroperitoneal and Open Pancreatic Necrosectomy in 394 Patients With Necrotizing Pancreatitis. Annals of Surgery, 263(5), 992-1001. doi:10.1097/SLA.0000000000001407
Pancreatic cancer
Weitz, J., Büchler, M. W., Sykes, P. D., Neoptolemos, J. P., Costello, E., Halloran, C. M., . . . Allen, P. J. (2016). Pancreatic cancer. In Oxford Textbook of Oncology (pp. 478-507). Oxford University Press. doi:10.1093/med/9780199656103.003.0040
Pancreatic cancer
Weitz, J., Büchler, M. W., Sykes, P. D., Neoptolemos, J. P., Costello, E., Halloran, C. M., . . . Allen, P. J. (2016). Pancreatic cancer. In Oxford Textbook of Oncology (pp. 478-507). Oxford University Press. doi:10.1093/med/9780199656103.003.0040_update_001
2015
What Is the Best Way to Identify Malignant Transformation Within Pancreatic IPMN: A Systematic Review and Meta-Analyses
Sultana, A., Jackson, R., Gilbert, T., Bostock, E., Psarelli, E., Cox, T., . . . Halloran, C. (2015). What Is the Best Way to Identify MalignantTransformation Within Pancreatic IPMN: A SystematicReview and Meta-Analyses. Clinical and Translational Gastroenterology, 6(12), e130. doi:10.1038/ctg.2015.60
Cathepsin D expression in pancreatic ductal adenocarcinoma (PDAC) cells increases proliferation and reduces survival of pancreatic cancer patients
Mahajan, U., Langhoff, E., Costello, E., Greenhalf, W., Halloran, C., Schwaiger, T., . . . Mayerle, J. (n.d.). Cathepsin D expression in pancreatic ductal adenocarcinoma (PDAC) cells increases proliferation and reduces survival of pancreatic cancer patients. Zeitschrift für Gastroenterologie, 53(08). doi:10.1055/s-0035-1559095
A single p53 mutation may predict survival in intraductal papillary mucinous neoplasms of the pancreas
Nicholson, J., Harrison, S., Yan, L., Howes, N., Hanna, T., Bullock, K., . . . Greenhalf, W. (2015). A single p53 mutation may predict survival in intraductal papillary mucinous neoplasms of the pancreas. Pancreatology, 15(3), S28-S29. doi:10.1016/j.pan.2015.05.131
Cathepsin D expression in pancreatic ductal adenocarcinoma (PDAC) cells increases proliferation and reduces survival of pancreatic cancer patients
Langhoff, E., Mahajan, U., Costello, E., Greenhalf, W., Halloran, C., Schwaiger, T., . . . Meyerle, J. (2015). Cathepsin D expression in pancreatic ductal adenocarcinoma (PDAC) cells increases proliferation and reduces survival of pancreatic cancer patients. Pancreatology, 15(3), S20. doi:10.1016/j.pan.2015.05.104
Crosstalk between hedgehog and Wnt signalling in the diseased pancreas
Brumskill, S., Barrera, L., Campbell, F., Andrews, T., Greenhalf, W., Halloran, C., . . . Costello, E. (2015). Crosstalk between hedgehog and Wnt signalling in the diseased pancreas. Pancreatology, 15(3), S26. doi:10.1016/j.pan.2015.05.123
Evaluation of stromal quantification in pancreatic ductal adenocarcinoma using a tissue microarray
Evans, A., Oldfield, F., Hand, K., Halloran, C., Campbell, F., Neoptolemos, J., . . . Costello, E. (2015). Evaluation of stromal quantification in pancreatic ductal adenocarcinoma using a tissue microarray. Pancreatology, 15(3), S22. doi:10.1016/j.pan.2015.05.112
Improved outcomes following minimal access vs open pancreatic necrosectomy in 394 patients with severe necrotizing pancreatitis. Comparison of two time periods
Gomatos, I., Halloran, C., Raraty, M., Evans, J., Ghaneh, P., Smart, H., . . . Neoptolemos, J. (2015). Improved outcomes following minimal access vs open pancreatic necrosectomy in 394 patients with severe necrotizing pancreatitis. Comparison of two time periods. Pancreatology, 15(3), S59. doi:10.1016/j.pan.2015.05.230
Simultaneous integration of microRNA and mRNA expression in the analysis of quiescent and activated human fibroblasts in the diseased pancreas
Barrera, L., Lane, B., Brumskill, S., Oldfield, F., Nunes, Q., Campbell, F., . . . Costello, E. (2015). Simultaneous integration of microRNA and mRNA expression in the analysis of quiescent and activated human fibroblasts in the diseased pancreas. Pancreatology, 15(3), S19-S20. doi:10.1016/j.pan.2015.05.103
The EUROPAC secondary screening for pancreatic cancer in familial pancreatic cancer and hereditary pancreatitis kindreds
Hanna, T., Greenhalf, W., Costello, E., Halloran, C., Ghaneh, P., Raraty, M., . . . Neoptolemos, J. (2015). The EUROPAC secondary screening for pancreatic cancer in familial pancreatic cancer and hereditary pancreatitis kindreds. Pancreatology, 15(3), S95. doi:10.1016/j.pan.2015.05.346
Use of gemcitabine-loaded superparamagnetic iron oxide nanoparticles against pancreatic cancer cells in an artificial circulatory model
Nandi, S., Sykes, P., Hasan, E., Barrow, M., Neoptolemos, J., Costello, E., . . . Halloran, C. (2015). Use of gemcitabine-loaded superparamagnetic iron oxide nanoparticles against pancreatic cancer cells in an artificial circulatory model. Pancreatology, 15(3), S22. doi:10.1016/j.pan.2015.05.111
41 Cathepsin D Expression in Pancreatic Ductal Adenocarcinoma (PDAC) Cells Increases Proliferation and Reduces Survival of Pancreatic Cancer Patients
Mahajan, U. M., Langhoff, E., Costello, E., Greenhalf, W., Halloran, C., Schwaiger, T., . . . Mayerle, J. (2015). 41 Cathepsin D Expression in Pancreatic Ductal Adenocarcinoma (PDAC) Cells Increases Proliferation and Reduces Survival of Pancreatic Cancer Patients. Gastroenterology, 148(4), S-13. doi:10.1016/s0016-5085(15)30041-x
Evidence of adjuvant chemotherapy of ductal pancreatic cancer
Sultana, A., Halloran, C., Palmer, D., Ghaneh, P., Cox, T., & Neoptolemos, J. P. (2015). Evidence of adjuvant chemotherapy of ductal pancreatic cancer. In PANCREATIC CANCER, CYSTIC NEOPLASMS, AND ENDOCRINE TUMORS: DIAGNOSIS AND MANAGEMENT (pp. 94-102). Retrieved from https://www.webofscience.com/
Biomarkers for early diagnosis of pancreatic cancer
Jenkinson, C., Earl, J., Ghaneh, P., Halloran, C., Carrato, A., Greenhalf, B., . . . Costello-Goldring, E. (2015). Biomarkers for early diagnosis of pancreatic cancer. Expert Review of Gastroenterology & Hepatology, 9(03), 305-315. doi:10.1586/17474124.2015.965145
Adjuvant Therapy in Pancreatic Cancer
Oldfield, F., Ghaneh, P., Jackson, R., & Halloran, C. (n.d.). Adjuvant Therapy in Pancreatic Cancer. International Journal of Digestive Diseases, 01(01). doi:10.4172/2472-1891.100003
Incidence of post-ERCP pancreatitis from direct pancreatic juice collection in hereditary pancreatitis and familial pancreatic cancer before and after the introduction of prophylactic pancreatic stents and rectal diclofenac.
Nicholson, J., Greenhalf, B., Jackson, R., Cox, T., Butler, J., Hanna, T., . . . Neoptolemos, J. (2015). Incidence of post-ERCP pancreatitis from direct pancreatic juice collection in hereditary pancreatitis and familial pancreatic cancer before and after the introduction of prophylactic pancreatic stents and rectal diclofenac.. Pancreas, 44(02), 260-265. doi:10.1097/MPA.0000000000000246
Investigating Gemcitabine-Loaded Superparamagnetic Iron Oxide Nanoparticles Against Pancreatic Cancer Cells in Artificial Circulation
Nandi, S., Sykes, P. D., Hasan, E., Barrow, M., Costello, E., Rosseinsky, M. J., . . . Halloran, C. M. (2015). Investigating Gemcitabine-Loaded Superparamagnetic Iron Oxide Nanoparticles Against Pancreatic Cancer Cells in Artificial Circulation. PANCREAS, 44(8), 1401. Retrieved from https://www.webofscience.com/
2014
Adjuvant therapy in pancreatic cancer
Jones, O. P., Melling, J. D., & Ghaneh, P. (2014). Adjuvant therapy in pancreatic cancer. WORLD JOURNAL OF GASTROENTEROLOGY, 20(40), 14733-14746. doi:10.3748/wjg.v20.i40.14733
Combination therapy using a novel Plk-1 inhibitor and gemcitabine in pancreatic cancer cells
Jones, O., Greenhalf, W. B., Halloran, C., & Ghaneh, P. (2014). Combination therapy using a novel Plk-1 inhibitor and gemcitabine in pancreatic cancer cells. Pancreatology, 14(3), S21. doi:10.1016/j.pan.2014.05.444
PORTAL HYPERTENSION DUE TO SPLANCHNIC VENOUS THROMBOSIS FOLLOWING OPEN OR SKUNK WIRE NECROSECTOMY OF ACUTE SEVERE PANCREATITIS
Britton, E. J., Mahoney, S., Garry, J., Halloran, C., & Richardson, P. (2014). PORTAL HYPERTENSION DUE TO SPLANCHNIC VENOUS THROMBOSIS FOLLOWING OPEN OR SKUNK WIRE NECROSECTOMY OF ACUTE SEVERE PANCREATITIS. In GUT Vol. 63 (pp. S252). doi:10.1136/gutjnl-2014-307263.541
Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.
Shaw, V. E., Lane, B., Jenkinson, C., Cox, T., Greenhalf, W., Halloran, C. M., . . . Costello, E. (2014). Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.. Molecular cancer, 13, 114. doi:10.1186/1476-4598-13-114
Serum cytokine biomarker panels for discriminating Pancreatic Cancer from Benign Pancreatic Disease
Shaw, V. E., Lane, B., Jenkinson, C., Cox, T. F., Greenhalf, W., Halloran, C. M., . . . Costello, E. (2014). Serum cytokine biomarker panels for discriminating Pancreatic Cancer from Benign Pancreatic Disease. Molecular Cancer, 13. Retrieved from https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-13-114
Prognostic markers in acute pancreatitis
Gomatos, I. P., Xiaodong, X., Ghaneh, P., Halloran, C., Raraty, M., Lane, B., . . . Neoptolemos, J. P. (2014). Prognostic markers in acute pancreatitis. Expert Review of Molecular Diagnostics: new diagnostic technologies are set to revolutionise healthcare, 14(3), 333-346. doi:10.1586/14737159.2014.897608
Develoment of superparamagnetic nano particles that specifically deliver intracellular chemotherapy to pancreatic cancer cell lines by antibody mediated magneto-taxis
Sykes, P. D., Nandi, S., Rossenisky, M., & Halloran, C. M. (2014). Develoment of superparamagnetic nano particles that specifically deliver intracellular chemotherapy to pancreatic cancer cell lines by antibody mediated magneto-taxis. Nature Nano.
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.
Greenhalf, W., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., Lamb, R. F., . . . Büchler, M. W. (2014). Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.. Journal of the National Cancer Institute, 106(1). doi:10.1093/jnci/djt347
2013
Prediction of the severity of acute pancreatitis on admission by urinary trypsinogen activation peptide: A meta-analysis
Huang, W., Altaf, K., Jin, T., Xiong, J. -J., Wen, L., Javed, M. A., . . . Xia, Q. (2013). Prediction of the severity of acute pancreatitis on admission by urinary trypsinogen activation peptide: A meta-analysis. WORLD JOURNAL OF GASTROENTEROLOGY, 19(28), 4607-4615. doi:10.3748/wjg.v19.i28.4607
Is the association of the p.N34S SPINK1 variant explicable by a high risk halpotype rather than the polymorphism?
Nicholson, J., Grant, J., Neoptolemos, J., Harrison, S., Halloran, C., Ghaneh, P., . . . Greenhalf, W. (2013). Is the association of the p.N34S SPINK1 variant explicable by a high risk halpotype rather than the polymorphism?. Pancreatology, 13(3), S9-S10. doi:10.1016/j.pan.2013.04.026
Prediction of invasive candidal infection in critically ill patients with severe acute pancreatitis
Hall, A. M., Poole, L. A. L., Renton, B., Wozniak, A., Fisher, M., Neal, T., . . . Hampshire, P. A. (2013). Prediction of invasive candidal infection in critically ill patients with severe acute pancreatitis. CRITICAL CARE, 17(2). doi:10.1186/cc12569
Detection of mutations in pancreatic juice collected from the duodenum by post secretin-aspiration is not reliable
Nicholson, J. A., Butler, J., Johnstone, M., Yan, L., Evans, J. C., Sarkar, S., . . . Greenhalf, W. (2013). Detection of mutations in pancreatic juice collected from the duodenum by post secretin-aspiration is not reliable. Pancreatology, 13(2), e60. doi:10.1016/j.pan.2012.12.265
In vitro assessment of a superparamagnetic iron oxide nanoparticle for targeting pancreatic cancer cells
Sykes, P., Olariu, C., Hasan, E., Lydon, D., Rubbi, C., Neoptolemos, J., . . . Halloran, C. (2013). In vitro assessment of a superparamagnetic iron oxide nanoparticle for targeting pancreatic cancer cells. Pancreatology, 13(2), e78. doi:10.1016/j.pan.2012.12.326
Pancreatic stents with diclofenac reduce the incidence of post ERCP pancreatitis in patients undergoing molecular screening of pancreatic juice for pancreatic cancer
Nicholson, J. A., Butler, J., Harrison, S., Greenhalf, W., Sutton, R., Halloran, C., . . . Lombard, M. (2013). Pancreatic stents with diclofenac reduce the incidence of post ERCP pancreatitis in patients undergoing molecular screening of pancreatic juice for pancreatic cancer. Pancreatology, 13(2), e60. doi:10.1016/j.pan.2012.12.264
Detection of mutations in pancreatic juice collected from the duodenum by post secretin-aspiration is not reliable
Nicholson, J. A., Butler, J., Johnstone, M., Yan, L., Evans, J. C., Sarkar, S., . . . Greenhalf, W. (2013). Detection of mutations in pancreatic juice collected from the duodenum by post secretin-aspiration is not reliable. Pancreatology, 13(1), e16. doi:10.1016/j.pan.2012.12.049
Is the Association of the p.N34S SPINK1 Variant Explicable by a High Risk Haplotype Rather Than the Polymorphism?
Nicholson, J. A., Grant, J., Johnstone, M., Harrison, S., Halloran, C. M., Raraty, M. G. T., . . . Greenhalf, W. (2013). Is the Association of the p.N34S SPINK1 Variant Explicable by a High Risk Haplotype Rather Than the Polymorphism?. In PANCREAS Vol. 42 (pp. 1372). Retrieved from https://www.webofscience.com/
Pancreatic stents with diclofenac reduce the incidence of post ERCP pancreatitis in patients undergoing molecular screening of pancreatic juice for pancreatic cancer
Nicholson, J. A., Butler, J., Harrison, S., Greenhalf, W., Sutton, R., Halloran, C., . . . Lombard, M. (2013). Pancreatic stents with diclofenac reduce the incidence of post ERCP pancreatitis in patients undergoing molecular screening of pancreatic juice for pancreatic cancer. Pancreatology, 13(1), e9. doi:10.1016/j.pan.2012.12.027
Pancreatic stents with diclofenac reduce the incidence of post ERCP pancreatitis in patients undergoing molecular screening of pancreatic juice for pancreatic cancer
Nicholson, J. A., Butler, J., Harrison, S., Greenhalf, W., Sutton, R., Halloran, C., . . . Lombard, M. (2013). Pancreatic stents with diclofenac reduce the incidence of post ERCP pancreatitis in patients undergoing molecular screening of pancreatic juice for pancreatic cancer. Pancreatology, 13(1), e15. doi:10.1016/j.pan.2012.12.047
Prediction of invasive candidal infection in critically ill patients with severe acute pancreatitis.
Hall, A., Poole, L., Renton, B., Wozniak, A., Fisher, M., Neal, T., . . . Hampshire, P. A. (2013). Prediction of invasive candidal infection in critically ill patients with severe acute pancreatitis.. Crit Care, 17(2), R49.
2012
Impact of service centralisation on outcomes for patients with pancreatic cancer
Johnstone, M., Halloran, C. M., Ghaneh, P., Sutton, R., Neoptolemos, J. P., & Raraty, M. G. T. (2012). Impact of service centralisation on outcomes for patients with pancreatic cancer. Pancreatology, 12(6), 575. doi:10.1016/j.pan.2012.11.253
Outcomes and prognostic factors following pancreaticoduodenectomy for cholangiocarcinoma
Melling, J., Thomas, A., Sykes, P., Jackson, R., Whelan, P., Campbell, F., . . . Ghaneh, P. (2012). Outcomes and prognostic factors following pancreaticoduodenectomy for cholangiocarcinoma. Pancreatology, 12(6), 585. doi:10.1016/j.pan.2012.11.285
Outcomes and prognostic factors following pancreaticoduodenectomy for cholangiocarcinoma
Melling, J., Thomas, A., Sykes, P., Jackson, R., Whelan, P., Campbell, F., . . . Ghaneh, P. (2012). Outcomes and prognostic factors following pancreaticoduodenectomy for cholangiocarcinoma. Pancreatology, 12(6), 567. doi:10.1016/j.pan.2012.11.226
Targeting pancreatic cancer cells in vitro with super-paramagnetic iron oxide nanoparticles
Sykes, P., Olariu, C., Hasan, E., Lydon, D., Costello, E., Rubbi, C., . . . Halloran, C. (2012). Targeting pancreatic cancer cells in vitro with super-paramagnetic iron oxide nanoparticles. Pancreatology, 12(6), 548. doi:10.1016/j.pan.2012.11.160
Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma The ESPAC-3 Periampullary Cancer Randomized Trial
Neoptolemos, J. P., Moore, M. J., Cox, T. F., Valle, J. W., Palmer, D. H., McDonald, A. C., . . . Buechler, M. W. (2012). Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma The ESPAC-3 Periampullary Cancer Randomized Trial. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 308(2), 147-156. doi:10.1001/jama.2012.7352
OC-057 10 Years on from the improving outcomes guidance—development of a tertiary pancreatic cancer unit
Johnstone, M., Halloran, C. M., Ghaneh, P., Sutton, R., Neoptolemos, J. P., & Raraty, M. G. T. (2012). OC-057 10 Years on from the improving outcomes guidance—development of a tertiary pancreatic cancer unit. Gut, 61(Suppl 2), A25.1-A25. doi:10.1136/gutjnl-2012-302514a.57
Nanotechnology advances in upper gastrointestinal, liver and pancreatic cancer
Sykes, P. D., Neoptolemos, J. P., Costello, E., & Halloran, C. M. (2012). Nanotechnology advances in upper gastrointestinal, liver and pancreatic cancer. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 6(3), 343-356. doi:10.1586/EGH.12.13
Chemotherapy and radiotherapy for pancreatic and periampullary cancer
Halloran, C. M., Ghaneh, P., & Neoptolemos, J. P. (2012). Chemotherapy and radiotherapy for pancreatic and periampullary cancer. In Blumgart's Surgery of the Liver, Pancreas and Biliary Tract (pp. 972-978.e2). Elsevier. doi:10.1016/b978-1-4377-1454-8.00063-1
Chapter 63A Chemotherapy and radiotherapy for pancreatic and periampullary cancer Adjuvant, neoadjuvant, and palliative
Halloran, C. M., Ghaneh, P., & Neoptolemos, J. P. (2012). Chapter 63A Chemotherapy and radiotherapy for pancreatic and periampullary cancer Adjuvant, neoadjuvant, and palliative. In Blumgart's Surgery of the Liver, Pancreas and Biliary Tract (pp. 972-978.e2). Elsevier. doi:10.1016/b978-1-4377-1454-8.00063-1
Molecular Biology of Pancreatic Cancer.
Sykes, P., Costello, E., Neoptolemos, J. P., & Halloran, C. M. (2012). Molecular Biology of Pancreatic Cancer.. In Oxford Textbook of Oncology (pp. TBC). Oxford: Oxford.
Nanotechnology advances in upper gastrointestinal, liver and pancreatic cancer.
Sykes, P. D., Neoptolemos, J. P., Costello, E., & Halloran, C. M. (2012). Nanotechnology advances in upper gastrointestinal, liver and pancreatic cancer.. Expert Rev Gastroenterol Hepatol., 6(3), 343-356.
2011
Multifunctional Fe<sub>3</sub>O<sub>4</sub> nanoparticles for targeted bi-modal imaging of pancreatic cancer
Olariu, C. I., Yiu, H. H. P., Bouffier, L., Nedjadi, T., Costello, E., Williams, S. R., . . . Rosseinsky, M. J. (2011). Multifunctional Fe<sub>3</sub>O<sub>4</sub> nanoparticles for targeted bi-modal imaging of pancreatic cancer. JOURNAL OF MATERIALS CHEMISTRY, 21(34), 12650-12659. doi:10.1039/c1jm11370d
Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater.
Neoptolemos, J. P., Moore, M. J., Cox, T. F., Valle, J. W., Palmer, D. H., Mcdonald, A., . . . Büchler, M. W. (2011). Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater.. Journal of Clinical Oncology, 29(18_suppl), LBA4006. doi:10.1200/jco.2011.29.18_suppl.lba4006
Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater.
Neoptolemos, J. P., Moore, M. J., Cox, T. F., Valle, J. W., Palmer, D. H., Mcdonald, A., . . . Büchler, M. W. (2011). Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater.. Journal of Clinical Oncology, 29(15_suppl), LBA4006. doi:10.1200/jco.2011.29.15_suppl.lba4006
Efficacy of stapler versus hand-sewn closure after distal pancreatectomy (DISPACT): a randomised, controlled multicentre trial
Diener, M. K., Seiler, C. M., Rossion, I., Kleeff, J., Glanemann, M., Butturini, G., . . . Buechler, M. W. (2011). Efficacy of stapler versus hand-sewn closure after distal pancreatectomy (DISPACT): a randomised, controlled multicentre trial. LANCET, 377(9776), 1514-1522. doi:10.1016/S0140-6736(11)60237-7
Chemotherapy and Radiotherapy: Adjuvant, Neo-Adjuvant and Palliative.
Halloran, C., Ghaneh, P., & Neoptolemos, J. P. (2011). Chemotherapy and Radiotherapy: Adjuvant, Neo-Adjuvant and Palliative.. In M. W. Buchler (Ed.), Blumgart's Surgery of the Liver, Pancreas and Biliary Tract, 5th Ed. (pp. 63A). Philadelphia: Elsevier.
Partial Pancreatic Resection for Pancreatic Malignancy Is Associated with Sustained Pancreatic Exocrine Failure and Reduced Quality of Life: A Prospective Study
Halloran, C. M., Cox, T. F., Chauhan, S., Raraty, M. G. T., Sutton, R., Neoptolemos, J. P., & Ghaneh, P. (2011). Partial Pancreatic Resection for Pancreatic Malignancy Is Associated with Sustained Pancreatic Exocrine Failure and Reduced Quality of Life: A Prospective Study. PANCREATOLOGY, 11(6), 535-545. doi:10.1159/000333308
Partial pancreatic resection for pancreatic malignancy is associated with sustained pancreatic exocrine failure and reduced quality of life: a prospective study
Halloran, C. M., Cox, T. F., Chauhan, S., Raraty, M. G., Sutton, R., Neoptolemos, J. P., & Ghaneh, P. (2011). Partial pancreatic resection for pancreatic malignancy is associated with sustained pancreatic exocrine failure and reduced quality of life: a prospective study. Pancreatology, 11(6), 535-545.
2010
Authors' reply: PBD treatment of cancer of the head of the pancreas
Neoptolemos, J. P., Lombard, M., & Halloran, C. M. (2010). Authors' reply: PBD treatment of cancer of the head of the pancreas. NATURE REVIEWS CLINICAL ONCOLOGY, 7(11). doi:10.1038/nrclinonc.2010.45-c2
Minimal Access Retroperitoneal Pancreatic Necrosectomy <i>Improvement in Morbidity and Mortality With a Less Invasive Approach</i>
Raraty, M. G. T., Halloran, C. M., Dodd, S., Ghaneh, P., Connor, S., Evans, J., . . . Neoptolemos, J. P. (2010). Minimal Access Retroperitoneal Pancreatic Necrosectomy <i>Improvement in Morbidity and Mortality With a Less Invasive Approach</i>. ANNALS OF SURGERY, 251(5), 787-793. doi:10.1097/SLA.0b013e3181d96c53
SURGICAL ONCOLOGY PBD-better stents in specialized centers are needed
Neoptolemos, J. P., & Halloran, C. M. (2010). SURGICAL ONCOLOGY PBD-better stents in specialized centers are needed. NATURE REVIEWS CLINICAL ONCOLOGY, 7(5), 244-246. doi:10.1038/nrclinonc.2010.45
ChroPac-Trial: Duodenum-preserving pancreatic head resection versus pancreatoduodenectomy for chronic pancreatitis. Trial protocol of a randomised controlled multicentre trial
Diener, M. K., Bruckner, T., Contin, P., Halloran, C., Glanemann, M., Schlitt, H. J., . . . Seiler, C. M. (2010). ChroPac-Trial: Duodenum-preserving pancreatic head resection versus pancreatoduodenectomy for chronic pancreatitis. Trial protocol of a randomised controlled multicentre trial. TRIALS, 11. doi:10.1186/1745-6215-11-47
Multifunctional nanoparticles for healthcare applications
Olariu, C. I., Yiu, H. P. P., Bouffier, L., Nedjadi, T., Costello, E., Halloran, C. M., & Rosseinsky, M. J. (2010). Multifunctional nanoparticles for healthcare applications. European Cells and Materials, 20(SUPPL.3), 192.
Surgical oncology: PBD-better stents in specialized centers are needed, a response
Neoptolemos, J. P., Halloran, C. M., & Lombard, M. G. (2010). Surgical oncology: PBD-better stents in specialized centers are needed, a response. Nature reviews clinical oncology - submitted.
2009
A spllen-preserving approach to pancreatic resection: Indications and complications
Gardener-Thorpe, J., Ghaneh, P., Wheelan, P., Joshi, H. M. N., Al-sarireh, B., Halloran, C. M., . . . Sutton, R. (2009). A spllen-preserving approach to pancreatic resection: Indications and complications. British Journal of Surgery.
2008
Le taux sérique de CA 19.9 préthérapeutique permet de sélectionner les patients candidats à une laparoscopie exploratrice visant à évaluer la résécabilité des cancers pancréatiques
Halloran, C. M., Ghaneh, P., Connor, S., Sutton, R., Neoptolemos, J. P., & Raraty, M. G. (2008). Le taux sérique de CA 19.9 préthérapeutique permet de sélectionner les patients candidats à une laparoscopie exploratrice visant à évaluer la résécabilité des cancers pancréatiques. Journal de Chirurgie, 145(4), 402. doi:10.1016/s0021-7697(08)74335-7
Carbohydrate antigen 19.9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancy
Halloran, C. M., Ghaneh, P., Connor, S., Sutton, R., Neoptolemos, J. P., & Raraty, M. G. T. (2008). Carbohydrate antigen 19.9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancy. BRITISH JOURNAL OF SURGERY, 95(4), 453-459. doi:10.1002/bjs.6043
2007
The EWTD 'triple whammy': hitting surgical trainees where it hurts
Heath, R. M., Gate, T. C. S., Halloran, C. M., Callaghan, M., Paraoan, M. T., & Blair, S. D. (2007). The EWTD 'triple whammy': hitting surgical trainees where it hurts. The Bulletin of the Royal College of Surgeons of England, 89(1), 26-28. doi:10.1308/147363507x161691
2005
Trials of gene therapy for pancreatic carcinoma
Halloran, C. M., Ghaneh, P., Costello, E., & Neoptolemos, J. P. (2005). Trials of gene therapy for pancreatic carcinoma. Current Gastroenterology Reports, 7(3), 165-169. doi:10.1007/s11894-005-0028-7
Combination Chemo-Gene Therapy for Pancreatic cancer
Halloran, C. (2005). Combination Chemo-Gene Therapy for Pancreatic cancer. (PhD Thesis, The University of Liverpool).
The european working time directive 'triple whammy': Hitting trainees where it hurts
Heath, R. E., Gate, T., Halloran, C., Callaghan, M., Paraoan, M., & Blair, S. D. (2005). The european working time directive 'triple whammy': Hitting trainees where it hurts. British Journal of Surgery, 92, 113.
Trials of gene therapy for pancreatic carcinoma.
Halloran, C. M., Ghaneh, P., Costello, E., & Neoptolemos, J. P. (2005). Trials of gene therapy for pancreatic carcinoma.. Current gastroenterology reports, 7(3), 165-169. doi:10.1007/s11894-005-0028-7
2004
Current standards of surgery for pancreatic cancer
Alexakis, N., Halloran, C., Raraty, M., Ghaneh, P., Sutton, R., & Neoptolemos, J. P. (2004). Current standards of surgery for pancreatic cancer. BRITISH JOURNAL OF SURGERY, 91(11), 1410-1427. doi:10.1002/bjs.4794
5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16<SUP>INK4A</SUP> greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells
Halloran, C. M., Ghaneh, P., Shore, S., Greenhalf, W., Zumstein, L., Wilson, D., . . . Costello, E. (2004). 5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16<SUP>INK4A</SUP> greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells. JOURNAL OF GENE MEDICINE, 6(5), 514-525. doi:10.1002/jgm.540
Novel Alternatives to Chemotherapy in Advanced Disease: Gene Transfer
Ghaneh, P., Halloran, C. M., Costello, E., & Neoptolemos, J. P. (2004). Novel Alternatives to Chemotherapy in Advanced Disease: Gene Transfer. In Pancreatic Disease (pp. 99-120). Springer London. doi:10.1007/978-1-85233-904-3_9
2003
Pancreatic adenocarcinoma - gene therapy is better adjuvant treatment than chemotherapy or radiotherapy
Halloran, C. M., Ghaneh, P., Neoptolemos, J. P., & Costello, E. (2003). Pancreatic adenocarcinoma - gene therapy is better adjuvant treatment than chemotherapy or radiotherapy. Pancreatology, 3(3), 245.
2002
Complications of pancreatic cancer resection
Halloran, C. M., Ghaneh, P., Bosonnet, L., Hartley, M. N., Sutton, R., & Neoptolemos, J. P. (2002). Complications of pancreatic cancer resection. DIGESTIVE SURGERY, 19(2), 138-146. doi:10.1159/000052029
Complications of pancreatic cancer resection
Halloran, C. M., Ghaneh, P., Bossnett, L., Hartley, M., Sutton, R., & Neoptolemos, J. P. (2002). Complications of pancreatic cancer resection. Digestive Surgery, 19(2), 138-146. doi:10.1159/000052029
The combined approach of Chemo-Gene therapy in the treatment of pancreatic adenocarcinoma
Halloran, C. M., Ghaneh, P., Neoptolemos, J. P., & Costello, E. (2002). The combined approach of Chemo-Gene therapy in the treatment of pancreatic adenocarcinoma. Pancreatology, 2(3), 322.
2001
Cytotoxic drugs combined with adenoviral-mediated introduction of tumour suppresser genes act synergistically to decrease pancreatic cancer cell viability
Halloran, C. M., Ghaneh, P., Neoptolemos, J. P., & Costello, E. (2001). Cytotoxic drugs combined with adenoviral-mediated introduction of tumour suppresser genes act synergistically to decrease pancreatic cancer cell viability. Pancreatology, 1(2), 164.
The effects of combining cytotoxic agents and adenoviral mediated introduction of tumour suppresser genes on pancreatic cancer cells
Halloran, C. M., Ghaneh, P., Neoptolemos, J. P., & Costello, E. (2001). The effects of combining cytotoxic agents and adenoviral mediated introduction of tumour suppresser genes on pancreatic cancer cells. Molecular Therapy, 3(5), 213-214.
gene therapy for pancreatic cancer; cobination of cytotoxic agents with adenoviral-delivered tumour suppresser genes increases cytopathic effect
Halloran, C. M., Ghaneh, P., Neoptolemos, J. P., & Costello, E. (2001). gene therapy for pancreatic cancer; cobination of cytotoxic agents with adenoviral-delivered tumour suppresser genes increases cytopathic effect. British Journal of Surgery, 88(1), 7.
2000
An investigation into the effects, on pancreatic cancer cells, of chemotherapeutic drugs and adenoviral-mediated delivery of p53 and p16
Halloran, C., Ghaneh, P., Greenhalf, W., Neoptolemos, J. P., & Costello, E. (2000). An investigation into the effects, on pancreatic cancer cells, of chemotherapeutic drugs and adenoviral-mediated delivery of p53 and p16. Molecular Therapy, 1(5), 325-326.
Fatal intestinal perforation secondary to fragmentation of a celestin tube
Evans, J. D., Halloran, C. M., Mansour, P., & Zeiderman, M. R. (2000). Fatal intestinal perforation secondary to fragmentation of a celestin tube. DIGESTIVE SURGERY, 17(4), 400-402. doi:10.1159/000018886
Gene therapy for pancreatic cancer - current and prospective strategies
Halloran, C. M., Ghaneh, P., Neoptolemos, J. P., & Costello, E. (2000). Gene therapy for pancreatic cancer - current and prospective strategies. SURGICAL ONCOLOGY-OXFORD, 9(4), 181-191. doi:10.1016/S0960-7404(01)00011-1
gene therapy for pancreatic cancer - current and propective strategies
Halloran, C. M., Ghaneh, P., Neoptolemos, J. P., & Costello, E. (2000). gene therapy for pancreatic cancer - current and propective strategies. Surgical Oncology, 9(4), 181-191.